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Synthetic glucocorticoids (GCs) such as dexamethasone (DEX), are given to pregnant 
women to reduce the incidence of respiratory distress syndrome and intraventricular hemorrhage 
in premature infants. However, animal and human studies reveal adverse effects of DEX on 
cerebral cortical development. Understanding the basis for these negative neurological 
consequences of prenatal GCs would be aided by a detailed description of the developmental and 
spatial expression profile of the glucocorticoid receptor (GR) in neural stem/progenitor cells. 
This could provide mechanistic understanding of the impact of premature activation of GR 
signaling in the developing brain, particularly since endogenous GC levels are low during the 
period of fetal development at which DEX is administered. In this study we show that GR 
protein is expressed in cortical radial glia cells (RGCs) and intermediate progenitor cells (IPCs) 
from embryonic day 11.5 in the mouse. Furthermore, in many areas of the fetal brain, GR was 
primarily nuclear at times when endogenous GCs are expected to be low. We also examined the 
consequences of prenatal DEX exposure and found that a single, clinically relevant DEX dose at 
midgestation (E14.5) reduced cortical thickness and surface on E17.5, but increased the number 
of neurons throughout the cortex, including in deep layer VI. BrdU birthdating revealed that the 
BrdU+ progeny of the E14.5 progenitors was increased by DEX. Furthermore, while a higher 
proportion migrated in the cortical plate, a smaller proportion remained in the progenitor zone, 
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suggesting that DEX promoted precocious neurogenesis. Accordingly, after a single, 24 hour 
exposure on E14.5, DEX induced a neurogenic fate shift in progenitors in an S-phase-specific 
manner. Specifically in non-S-RGCs DEX promoted the IPC fate, while it induced re-entry of S-
phase RGCs and expansion primarily of the neurogenic RGC pool (BrdU+). DEX induced 
neurogenic divisions of S-phase RGCs and S-phase IPCs causing increase of the BrdU+ cells. 
FACs analysis verified the neurogenic shift in S-phase BrdU+ progenitors, which accumulated in 
G0G1 phase. Collectively, these results suggest that premature, DEX-induced activation of GR 
induces cell cycle phase-dependent precocious neurogenesis and highlights a role for GR in 
regulating neurogenesis in the developing brain. 
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PREFACE 
Ithaka 
Constantine P. Cavafy 
 
As you set out for Ithaka 
hope the voyage is a long one, 
full of adventure, full of discovery. 
 
Laistrygonians and Cyclops, 
angry Poseidon—don’t be afraid of them: 
you’ll never find things like that on your way 
as long as you keep your thoughts raised high, 
as long as a rare excitement stirs your spirit and your body. 
 
Laistrygonians and Cyclops, 
wild Poseidon—you won’t encounter them 
unless you bring them along inside your soul, 
unless your soul sets them up in front of you. 
 
Hope the voyage is a long one. 
May there be many a summer morning when, 
with what pleasure, what joy, 
you come into harbors seen for the first time; 
 xvi 
may you stop at Phoenician trading stations 
to buy fine things, 
mother of pearl and coral, amber and ebony, 
sensual perfume of every kind— 
as many sensual perfumes as you can; 
and may you visit many Egyptian cities 
to gather stores of knowledge from their scholars. 
 
Keep Ithaka always in your mind. 
Arriving there is what you are destined for. 
But do not hurry the journey at all. 
Better if it lasts for years, 
so you are old by the time you reach the island, 
wealthy with all you have gained on the way, 
not expecting Ithaka to make you rich. 
 
Ithaka gave you the marvelous journey. 
Without her you would not have set out. 
She has nothing left to give you now. 
 
And if you find her poor, Ithaka won’t have fooled you. 
Wise as you will have become, so full of experience, 
you will have understood by then what these Ithakas mean. 
 
 
C.P. Cavafy, Collected Poems. Translated by Edmund Keeley and Philip Sherrard.  
Edited by George Savidis. Revised Edition. Princeton University Press, 1992 
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 1 
INTRODUCTION 
1.1 GLUCOCORTICOIDS AND THE GLUCOCORTICOID RECEPTOR 
1.1.1 Glucocorticoids: Historical Perspective 
Glucocorticoids (glykos, Greek: sweet + cortex, GCs), are steroid hormones produced by the 
zona fasciculata of the adrenal cortex. These hormones are indispensable for life, since they act 
in nearly all organ systems and cells of the body. They regulate a multitude of processes 
spanning many organizational levels: from regulation of the cell cycle, organ development 
including the brain, cardiovascular function, metabolic and immune processes, reproduction and 
cognitive functions. Due to their powerful immunosuppressive properties, GCs and their 
synthetic forms (sGCs), are amongst the most prescribed drugs for the treatment of inflammatory 
and auto-immune diseases such as allergies, rheumatoid arthritis and multiple sclerosis ((Oakley 
and Cidlowski, 2013) and references therein). Also, they have been used along the first line of 
defense in cancer and especially in cancers of the lymphoid system such as leukemia and 
lymphoma. The immunosuppressive effects or cortisone, the precursor molecule of cortisol (or 
hydrocortisone), were first discovered by Philip Showalter Hench (MD at the University of 
Pittsburgh and then of Mayo Clinic) when he showed that it can alleviate the pain symptoms 
associated with rheumatoid arthritis. Along with Tadeus Reichstein and Edward Calvin Kendall, 
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they shared the Nobel Prize for Physiology or Medicine in 1950, for discovering the production 
of cortisone in the adrenal glands, its structure and functions (Figure 1). GCs are instrumental in 
the stress response, first noted by Hans Selye in 1936 when he published a not more than a half-
page report in Nature noting the common characteristics of animals exposed to various noxious 
stimuli, including enlargement of the adrenals 1, later named by Selye as the “stress syndrome”. 
Hans Selye, also discovered the Hypothalamus-Pituitary Adrenal axis (HPA axis), which 
controls the stress response. In addition, Selye proposed that GCs are critical regulators of 
homeostasis or of the internal mileau, which was first noted by Claude Bernard and then adapted 
by Walter Cannon. Cannon is credited for the proposal of the “fight or flight response” and the 
integration of the central nervous system response with the adrenal function to maintain 
homeostasis2 (Figure 2). 
 
 
 
 
 
 
 
 
 
 
                                                 
1
 http://brainimmune.com/hans-selye-and-the-birth-of-the-stress-concept/ 
2 http://brainimmune.com/walter-cannon-homeostasis-the-fight-or-flight-response-the-sympathoadrenal-   
system-and-the-wisdom-of-the-body/ 
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Figure 1. Philip Showalter Hench, Edward Calvin Kendall and Tadeus Reichstein 
They shared the 1950 Nobel prize in Medicine "for their discoveries relating to the hormones of the 
adrenal cortex, their structure and biological effects". Source "The Nobel Prize in Physiology or Medicine 
1950". Nobelprize.org. Nobel Media AB 2013. Copyright © The Nobel Foundation. 
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Figure 2. Hans Selye and the Hypothalamus-Pituitary-Adrenal Axis (Adapted from Berczi, 2009) 
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1.1.1.1 Steroidogenesis in the embryo 
Cortisone is synthesized de novo by cholesterol. The generation of the active form of the 
hormone, cortisol in primates and corticosterone in rodents, is catalyzed by 11β -hydorxysteroid 
dehydrogenase type 1 (11β-HSD1) (Figure 3B). This reaction is bidirectional, whereby, cortisol 
can be degraded to its inactive keto-forms cortisone and 11-dehydrocorticosterone by 11β-HSD2. 
In the human placenta, 11β-HSD2 is expressed in high levels and protects the embryo from 
exposure to high levels of maternal GCs (Benediktsson et al., 1997). The human fetal adrenal can 
produce de novo cortisol in the fetal zone, a specialized section of the fetal adrenal, from the first 
trimester. The production is transient and the physiological significance of cortisol production at 
this stage is not clear. The expression of 2 3β-hydroxysteroid dehydrogenase/Δ4-5 isomerase 
(HSD3B2), which is required for de novo GC production, is suppressed and its levels start to 
increase in the fetal adrenal approximately from week 24 and is more pronounced in late-
gestation (Ishimoto and Jaffe, 2011). This late increase in GC production, reflects the growth 
stimulating property of GCs, as they promote organ maturation, stimulation of lung surfactant 
production and prepare the fetus for forthcoming birth.  In the mouse, which is used by many 
groups as a model for studying the GC actions, endogenous production of GCs in the embryo is 
established around E16 (Venihaki et al., 2000). The morphogenesis and function of the human 
adrenal is largely driven by ACTH, although these results need still more investigation, since 
their majority have been generated ex vivo or in vitro. The placenta (or better ascribed as the 
feto-placenta unit) plays a key role in fetal adrenal development and the activation of the HPA 
axis. A hypothetical model of how this happens is suggested by Ishimoto & Jaffe (2011). Close 
to term the feto-placental unit secretes Corticotropin-releasing hormone (CRH) stimulating 
cortisol production in the fetal adrenal and upregulation of ACTH receptors (ACTHR) and 
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thereby sensitizing the fetal adrenals to ACTH and thereby establishing the fetal HPA axis. 
Cortisol promotes organ maturation including the lungs (Bolt et al., 2001), while placental CRH 
and cortisol stimulate the increase of prostaglandins which initiate the process of parturition. For 
a detailed review of the human adrenal development the reader is directed to the review by 
Ishimoto & Jaffe (2011).  In the mouse, the HPA axis feedback loop, is established at E16 
(Reichardt and Schutz, 1996), coincidently with the initiation of the production of endogenous 
GCs. Different internal or external signals such as circadian rhythms or stress induce the release 
of CRH from the paraventricular nucleus of the hypothalamus, which then is transported through 
the portal circulation to the anterior pituitary and promotes synthesis and secretion of ACTH. 
Subsequently, ACTH acts on the adrenal cortex and promotes the production of GCs. Due to a 
negative feedback loop between the Hypothalamus-Pituitary and Adrenals, increasing levels of 
GCs inhibit the secretion of CRH in the hypothalamus and ACTH from the pituitary. This 
negative loop is established by GC action on glucocorticoid receptors (GRs), (Figure 3A). 
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Figure 3. The Hypothalamus Pituitary Adrenal (HPA) Axis and GC metabolism 
A.  High levels of GCs exert a negative feedback control on the hypothalamus and pituitary and inhibit 
their stimulatory effect on the adrenals until GC levels return to equilibrium. B. Cortisol is degraded to 
inactive cortisone by 11β-HSD2 and vice versa by 11β-HSD1. 11β-HSDs along with plasma proteins, 
regulate the levels of available bioactive cortisol. Placental 11β-HSD2 is particularly important during the 
embryo development, since it degrades the maternal GCs and protects the embryo by potential damage 
from high maternal GCs. 
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1.1.2 GR Biology and Signaling  
The intracellular effects of GCs are mediated through the corticosteroid receptors: the GR and 
the mineralocorticoid receptor (MR). MR has a greater sensitivity to cortisone than GR, and can 
be activated by lower concentrations of GC but is also responsive to mineralocorticoids such as 
aldosterone, hence its name. Its expression is more restricted compared to GR which is expressed 
in almost all cells of the body, therefore GR is the primary mediator of GC actions. GR belongs 
to the family of steroid nuclear hormone receptors and in the subfamily of nuclear receptors 
(NRs), hence its gene symbol NR3C1. The human GR is encoded on chromosome 5 between 
loqi 5q31-q32 (Hollenberg et al., 1985), whereas in the mouse the GR gene is located on 
chromosome 18 (Danielsen et al., 1986). 
The GR protein has a modular structure with 3 main domains: the N-terminal transactivation 
domain (NTD), the central DNA-binding domain (DBD) which is separated by the C-terminal 
ligand-binding domain (LBD) by a flexible hinge region (H), (Figure 4). GCs are bound by a 
hydrophobic pocket which is formed by twelve alpha-helices and four beta-sheets within the 
LBD. Nuclear localization of the receptor is controlled by two nuclear localization signals NL1, 
located within the DBD/hinge region and NL2 which is in the LBD. The NL1 signal has been 
associated with a ligand independent localization of GR, which is dependent on the cell cycle 
phase (Matthews et al., 2011). The receptor harbors two transactivation domains AF1 located in 
the NTD and AF2 found in the LBD. The latter is associated with ligand-dependent 
transactivation of the receptor whereas the former has recently been associated with ligand 
independent GR signaling (Matthews et al., 2011). Within the DBD, two zinc finger motifs 
recognize special DNA elements within target genes that are called glucocorticoid responsive 
elements (GREs). The consensus GRE sequence is an imperfect palindrome composed by two 
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half-sides, 6 bp each: GGAACAnnnTGTTCT. The ligand-activated GR binds these sequences as 
a homodimer and promotes transcription of target genes, and the spacer region (nnn) is 
instructive for the GR homodimer to bind the DNA. However, GR can also repress gene 
transcription and this mechanism is associated either by interactions with other cofactors, 
changes in the chromatin landscape or by binding to negative-GREs. The sequence of negative-
GREs differs from the sequence of the canonical GRE, in that the spacer is of variable size: 
CTCC(n) 0-2 GGAGA. Also, two GR receptors bind the nGRE but do not homomerize (Hudson 
et al., 2013; Lightman and George, 2014; Oakley and Cidlowski, 2013; Surjit et al.). The 
chromatin landscape is a critical regulator of GR action, since the majority of GR binding sites 
are within strongly DNase I–sensitive regions of the genome, in hormone-free conditions (John 
et al., 2011). This is very important considering the growth-promoting role of GCs, and also 
because chromatin remodeling is a dynamic process and integral determinant of cell fate 
determination during development, including brain development (Ho and Crabtree, 2010; 
Lessard et al., 2007). Moreover, differences in chromatin accessibility may underlie the tissue-
specific effects of GCs. 
1.1.2.1 Classic GR signaling  
In the classical scheme of GR signaling, the GC-free receptor is located in the cytoplasm of the 
cell in association with chaperone proteins and immunophilins such as FKBP51 and FKBP52. 
Once the receptor, binds to a GC ligand then the protein complex is dissociated and the GC-GR 
complex is shuttled into the nucleus to act on gene targets, either by inducing or suppressing 
their expression. Moreover in addition to binding directly to the DNA as a homodimer, GR can 
regulate gene expression through physical association with other transcription factors and by 
binding directly on the DNA or indirectly through regulation of the associated co-factor function. 
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The transcriptional effects of the classical GR signaling pathway require substantial time to take 
place that can range up to hours. Interestingly, at high concentrations of GR, the receptor can 
form hormone-free dimers and bind DNA, which may enhance transactivation potency of the 
receptor following a subsequent GC exposure (Robertson et al., 2013). 
1.1.2.2 Non-Classical Rapid GR signaling  
Beyond the classical GR pathway which is executed by nuclear GR, membrane associated GRs 
can mediate rapid effects of GCs in great part through kinase cascades that do not primarily 
require changes in gene expression. Changes in cellular processes as a result of rapid GR 
signaling can be initiated as rapidly as a few seconds (Lau et al., 2013; Oakley and Cidlowski, 
2013{Popoli, 2012 #254; Popoli et al., 2012). Fast actions of GC-GR signaling have been 
studied within the context of the effects of stress on neurotransmission (Tasker et al., 2006). In 
the prefrontal cortex, a GR-specific mechanism participates in endocannabinoid production and 
release regulating in this manner synaptic function of the affected neurons (Popoli et al., 2012). 
Dexamethasone (DEX), a specific GR agonist, induces an increase in the dendritic spines in CA1 
pyramidal neurons within 1 h, in adult male rat hippocampus (Groeneweg et al., 2011; 
Komatsuzaki et al., 2005; Komatsuzaki et al., 2012). Also, DEX can rapidly induce the cell 
surface expression of the serotonin transporter in embryonic stem cell-derived serotonergic 
neurons (Lau et al., 2013). In addition, rapid GR signaling can modulate GABA-ergic 
neurotransmission in the rat prefrontal cortex and hippocampus and thus affect spontaneous 
activity in these areas (Teng et al., 2013). Membrane-bound GR in association with caveolin 1 
(Cav1), can directly affect cell cycle progression in neural stem cells in culture and in A549 lung 
epithelial cells (Matthews et al., 2008b; Peffer et al., 2014; Samarasinghe et al., 2011). 
Activation of GR by DEX, promotes phosphorylation of Cav1 and protein kinase B (PKB)/Akt 
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via the src kinase and leads to growth arrest and accumulation in G1/S (Matthews et al., 2008b). 
This pathway is also functional in neural stem cells in vitro and regulates their proliferation 
(Peffer et al., 2014; Samarasinghe et al., 2011).  Moreover, in the A549 cells, Cav1-dependent 
rapid GR signaling, promotes the activation of glycogen synthase kinase-3β (Gsk-3β) and of the 
mammalian target of rapamycin (mTOR) implicating further the PI3K kinase pathway in the 
rapid effects of GCs.  
1.1.2.3 Ligand independent GR signaling  
Beyond its classic role as mediating the effects of GCs, the GR is itself a transcription factor. As 
discussed above, the GR can regulate chromatin structure and in association with other 
transcription factors or co-factors, can modulate gene expression. It was recently shown that GR 
can function in the absence of GC binding to regulate gene transcription. Specifically, GR 
directly binds the promoter of the BRCA1 gene in association with the co-factor GABP, and 
promotes BRCA1 expression in mammary cells. This relation is specific to GC-naïve conditions 
and is abolished in the presence of hydrocortisone (Ritter et al., 2012). Furthermore, microarray 
analysis revealed that this basal regulation of gene expression by GR in the absence of GCs is 
not limited to BRCA1 but applies to many other genes, which are critical for organ development 
such as cyclin D2 (Ritter and Mueller, 2014). Moreover in proliferating cells, the subcellular 
localization and function of the unliganded GR is tightly regulated by the cell cycle phase 
(Matthews et al., 2011). NL1-dependent nuclear accumulation of GR occurs throughout the 
interphase (middle G1-G2 phases), whereas during mitosis and until early G1 the receptor is 
excluded from the nucleus. Ligand-independent transactivation of the receptor is induced during 
G2/M by phosphorylation of GR on the Ser211, which is located within AF1. These data suggest 
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that the subcellular localization of GR under basal conditions in proliferating cells is tightly 
linked to GC response. 
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Figure 4. Modular structure of the GR protein and GR signaling, classical and non-classical.  
A. The GR protein consists of the N-terminal domain (NTD) which contains the activation domain 1 
(AF1), the DNA-binding domain (DBD), a hinge region (H) and the carboxy-terminal Ligand-Binding 
Domain (LBD). The LBD also contains an AF (AF2). The NTD domain is the target for many post-
translational modifications mainly of phosphorylation on Serine residues. Shown is Ser211, which is very 
important for ligand-independent function of GR. B. The classical and non-classical GR signaling are 
ligand-dependent (ligand are depicted with stars). The classical or genomic signaling pathway is mediated 
by cytosolic GR, which after GC-binding, translocates in the nucleus and promotes changes in gene 
transcription. The non-classical or rapid non-genomic pathway is mediated by membrane bound GR, is 
executed through kinase cascades and does not primarily promote gene transcription changes. Also 
shown, is the ligand-independent GR signaling, which regulates gene transcription in the absence of GC 
ligand. 
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1.1.2.4 A plethora of GR variants 
The main transcript derived from the GR gene is the GRα, representing the classic GR receptor 
protein, with a length of 777 amino acids (aa). Alternative splicing of exon 9, gives rise to GRβ, 
consisting only by 742 aa. In contrast to GRα, the GRβ isoform, is localized in the nucleus 
constitutively. When the two isoforms are colocalized, the GRβ form antagonizes GRα action by 
forming heterodimers that cannot induce transcriptional activation (Oakley and Cidlowski, 
2013).  Interestingly, the GRβ isoform can function in signaling pathways that are independent of 
GCs (Stechschulte et al., 2014). Alternative splicing in other exons generates three additional 
main isoforms GRγ, A and P. Furthermore, alternative translation initiation sites from the GRα 
mRNA give rise to different subtypes of GRα {-A, -B, -C1-3, -D1-3}, each one with distinct 
transcriptional profiles. Most notable are the GRα-D variants that are constitutively located in the 
nucleus and can regulate gene expression independent of GCs. During human brain development 
and in aging, the expression of GRα variants changes (Sinclair et al., 2011). Intriguingly the D 
variant was found to be increased in the brain in cases of neuropsychiatric disorders such as 
schizophrenia implicating altered GR signaling in the pathogenesis of a number of brain 
disorders (Oakley and Cidlowski, 2013).  
Another level of regulation of GRs’ function occurs at the post-translational level. 
Specifically, in response to GC binding the GR can be modified by phosphorylation, 
ubiquitylation, SUMO-ylation or acetylation. Each of these post-translational modifications 
alters the ability of the receptor to act on gene targets (Oakley and Cidlowski, 2013). 
Phosphorylation is the most common and most widely characterized of the modifications of the 
receptor and takes place on serine, threonine, or tyrosine residues located in the NTD. MAPKs, 
glycogen synthase kinase 3β and cyclin dependent kinases are amongst the most common 
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kinases that phosphorylate GR in response to GC stimulation. Consequences of phosphorylation 
can range from alteration of the transcriptional activity of the receptor, changes in cofactor 
recruitment, degradation of the GR or changes in the subcellular distribution of the receptor. 
Interestingly, phosphorylation of the human GR has been shown on Ser134, as a result of cellular 
stress, but in hormone free conditions, suggesting a role for GR in mediating the effects of 
stressful stimuli. For an in detail analysis of the GR receptor biology and signaling the reader is 
directed to the in depth reviews by Galliher-Beckley and Cidlowski (2009) and Oakley and 
Cidlowski (2013). 
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1.2 GC USE DURING PREGNANCY 
1.2.1 Synthetic GCs 
GCs have a plethora of actions and target tissues and are amongst the most prescribed 
medications in world. Because the endogenous GC form cortisol can be degraded from 
11βHSD2, several synthetic forms of GCs (sGC) have been developed that are resistant to 
11βHSD2 degradation such as BETA and DEX. The majority of total cortisol (95%), is bound to 
plasma proteins, ~77% is bound on corticosteroid binding globulin (CBG) and ~ 12% on 
albumin (Tegethoff et al., 2009). sGCs are more potent and have greater biological activities 
compared to cortisol, because they have a lower binding affinity to plasma proteins (Table 1.1). 
Biological half-life is defined as the duration of measurable biological activity. Both DEX and 
BETA are long acting GCs, with a biological half-life ranging from 36-54 hours, compared to 
cortisol which is short acting and has a biological half-life between 8-12 hours (Tegethoff et al., 
2009). Moreover, the affinity and efficacy of sGCs in activating the genomic actions of GR are 
also higher compared to cortisol. BETA and DEX have a 25-fold higher potency in activating 
genomic GR signaling (BETA is slightly more potent than DEX). Also, sGCs have greater 
potency in activating non-genomic GR signaling compared to cortisol, with DEX being more 
than 5 fold higher of BETA (Grossmann et al., 2004; Tegethoff et al., 2009).  
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Table 1. Pharmacokinetic characteristics of Cortisol, Dexamethasone and Betamethasone in Humans 
 
1.2.2 Use of sGCs in prenatal medicine 
Glucocorticoids have been prescribed for use during pregnancy for many reasons including, 
maternal allergies and asthma. Synthetic GCs are also administered early in pregnancy when the 
fetus is suspected to suffer from congenital adrenal hyperplasia, an autosomal recessive 
condition resulting from mutations in the steroidogenic enzymes producing cortisol from 
cholesterol. This condition can affect both females and males and in its severe form, although not 
as common, results in virilization of the genitalia in females due to excess androgen production 
(Khalid et al., 2012). Due to the distress in later life associated with the ambiguous genitalia in 
females, DEX administration from the first trimester has been used as a treatment. Nevertheless, 
the malleability of this developmental period and the potential side-effects of DEX on embryo 
development have put this treatment under scrutiny. Another –unfortunately- common condition 
in which GCs are used, is preterm labor. Preterm labor is defined as birth before 37 weeks of 
gestation, with the normal range of human pregnancy spanning from 38-42 weeks. 
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Unfortunately, as the Born2Soon Global report 3 documented in 2012, more than 15 million 
babies are born prematurely each year, with over a million of babies dying as a result of 
complications from preterm birth (Lancet, 2012). Amongst the most common complications are 
intraventricular hemorrhage (IVH), as a result of an immature vasculature of the germinal matrix 
and development of respiratory distress syndrome (RDS) due to immaturity of the lungs. The 
germinal matrix is a proliferative zone of the human brain, which gives rise to neurons and glia, 
which migrate towards the developing cortex. It is highly vascularized, and the vasculature 
network is very delicate and thus highly sensitive to perturbations. The respiratory system 
matures during late gestation, during which type II pneumonocytes produce and secrete 
surfactant that allows the expansion of the lungs and prevents atelectasis of the lungs during 
breathing. In babies born before 37 weeks the pulmonary surfactant production is non-adequate 
or immature, and thus these babies have to spend the first stages of their life on a ventilator and 
supplied with exogenous surfactant. sGCs have been shown to reduce the mortality and 
morbidity associated with preterm birth by reducing the incidence of IVH and RDS. The 
mechanism of IVH reduction is not entirely clear but a stabilization of the germinal vasculature 
may be part of how sGCs act. In the case of RDS, sGCs reduce its incidence and the time 
preterm babies remain attached to a ventilator by promoting lung maturation and lung surfactant 
production.  
                                                 
3 WHO | Born Too Soon: The Global Action Report on Preterm Birth 
http://www.who.int/pmnch/media/news/2012/preterm_birth_report/en/ 
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1.2.3 Use of sGCs for premature labor: Historical Perspective 
The use of sGCs for the treatment of adversities resulting from premature labor, was pioneered 
by Sir Graham Collingwood Liggins (Figure 5). Dr. Liggins had devoted a great part of his 
research attempting to discover the trigger of premature birth using sheep as a model since many 
features of their pulmonary development is similar to humans. His observations that in utero 
exposure of premature lambs to GCs reduced the incidence and the severity of RDS (Liggins, 
1969) lead to the seminal randomized and controlled-study in humans, where along with his 
colleague Dr. Ross Howie they showed that antenatal BETA can lead to a 2-fold reduction in 
RDS and a 5-fold reduction in the mortality of premature babies (Liggins and Howie, 1972).  
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Figure 5. Sir Graham (Mont) Liggins  
Dr Liggins pioneered the use of synthetic glucocorticoids for the management of preterm labor saving the 
life of many preterm babies (Source: MacDonald, N., Dominion Post 2010 (MacDonald 2010). 
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1.2.4 Current status of sGC use during pregnancy  
Following the seminal discoveries of Dr. Liggins, sGCs have been adopted as a standard 
treatment for the management of preterm labor, with DEX and BETA being the most common 
forms used (Braun et al., 2013; Lancet, 2012; Tegethoff et al., 2009). The current dose regime to 
avoid premature labor complications between weeks 24-34, is a dose of 24 mg given 
intramuscularly. DE is given as 4 doses of 6 mg every 12 hours, whereas BETA is given in 2 
doses of 12 mg, 24 hours apart. As of 2013, the 18th World Health Organization model list of 
essential medicine, only includes DEX for the management of premature labor4. Depending on 
the development of the pregnancy, i.e., if preterm labor does not take place, more than one 
course of sGCs may be given.  
 
Nevertheless, sGC treatment has limitations on its effectiveness. Specifically, sGCs are most 
efficient in reducing RDS and IVH when given between 26-34 weeks and these benefits are 
limited for a time of 1-7 days following the first dose. The benefits before 26 weeks are not clear, 
whereas after 34 weeks there are questions whether the benefits outweigh the potential 
neurological side-effects on the developing brain (Roberts and Dalziel, 2006). 
 
 
 
                                                 
4 18th WHO List of Essential Medicines, April 2013 
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1.3 EFFECTS OF GCS ON THE DEVELOPING BRAIN 
Despite their benefits in reducing the mortality and morbidity associated with preterm labor, 
antenatal exposure to sGCs can damage developing fetal organs including the brain. 
Accumulating evidence from human and animal studies support the hypothesis that in utero 
exposure to sGCs may affect the functioning of the HPA axis, providing a basis for altered 
endocrine system function in the offspring, which is then associated with an increased risk for 
metabolic, cardiovascular problems in later life. Also, due to the intimate link of the HPA axis to 
the hippocampal and other limbic areas including the prefrontal cortex, excessive levels of GCs, 
including those resulting from maternal stress, increase the risk for affective and 
neuropsychiatric disorders (Huang, 2011; Lupien et al., 2009).  
1.3.1 Animal Studies 
Due to the ethical constraints associated with human studies, animal models have provided 
valuable information in delineating the effects of GCs on the developing brain. Early studies 
done in the late 80s, when the use of sGCs started to increase in clinical settings, revealed that 
DEX exposure in utero can impair cortical and hippocampal development (Uno et al., 1990; Uno 
et al., 1994). Specifically, in rhesus monkeys exposed to DEX one month before birth, the 
cortical and hippocampal structures were hypoplastic, the pyramidal layers of the hippocampus 
severely underdeveloped and the cell somata were smaller. Moreover, the effect of DEX on the 
hippocampus was long-lasting since at 9 months of age the hippocampal volume was still smaller 
in the DEX-treated animals (Uno et al., 1990). Additional effects that prenatal sGCs may have 
include retardation of brain development (Carlos et al., 1992; Huang et al., 1999) and apoptosis 
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and reduction in the size of the postmitotic neurons (Kreider et al., 2006).  Huang et al. (1999) 
evaluated the effects of a single versus multiple doses of BETA, on brain development in sheep. 
The effects on brain growth were evident even with the single dose, resulting in a reduction in 
cerebral length and depth and also to a reduction in whole brain weight at birth. Moreover, 
following antenatal sGC treatment in mice there have been reports of delayed neuronal migration 
in the cortex (Fukumoto et al., 2009), decreased proliferation of the hippocampus, accompanied 
by reduced LTD, impaired spatial learning, and reduction in the lifespan of the animals (Khozhai 
and Otellin, 2008; Noorlander et al., 2006; Noorlander et al., 2008). The same group reported a 
transient effect of DEX in increasing hippocampal apoptosis and reduction of the proliferation in 
the subgranular zone of the dentate gyrus upon birth, which was not observed in adult animals 
(Noorlander et al., 2014). In addition, Theodore Slotkin’s group has demonstrated that even 
when rats are exposed in utero at doses of DEX well below the clinically relevant range, there 
are still long-lasting changes in brain development including growth inhibition and neuronal loss, 
alterations in synaptic activity and cell signaling, specifically in adenylyl cyclase (AC) in the 
cerebral cortex, hippocampus, and the striatum (Kreider et al., 2006). Finally, perinatal DEX 
exposure can stunt cerebellar development and cause apoptosis in the external granular layer 
(Heine and Rowitch, 2009; Heine et al., 2010; Noguchi, 2014).  
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Table 2. Summary of the effects of in utero GC exposure on various aspect of fetal growth and 
development, including of neural development in humans and animal models. Adapted from Braun et al. 
(2013).  
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1.3.2 Human Studies 
The effects of antenatal GCs on human brain development have been the debate of many studies 
mainly due to the fact that it is difficult to achieve a randomized controlled study of this kind. 
Nevertheless, accumulating data from clinical studies are also pointing to an ambiguous role of 
antenatal GCs on brain development and putatively long term effects on the physiology of the 
offspring. Evaluation of the persons that were part of the original Liggins cohort 30 years later, 
revealed that adults exposed to a single dose of BETA had developed insulin resistance (Dalziel 
et al., 2005). Murphy et al. (2012), showed that multiple courses of antenatal GCs are associated 
with a reduction in birth weight and head circumference even after controlling for gestational age 
at birth. In addition, the authors noted that there was a trend for each additional course of GCs to 
correlate with incremental decreases in birth weight and head circumference. Normal variations 
in birth weight are strongly associated with cortical surface area and total brain volume, and thus 
correlates with later neural development (Walhovd et al., 2012). Within this context, repeated 
courses of GCs have been associated with delayed development and adverse mental health in 
childhood and adolescence (Khalife et al., 2013). Premature birth is itself associated with a 
number of complications that may impinge on brain development thus confounding any effects 
on brain development that can be attributed solely to antenatal GC exposure. In recognition of 
this fact, studies have aimed at collecting available data from children that were exposed to GCs 
antenatally, but were born at term (Waffarn and Davis, 2012). At this point it is important to note 
that 25-30% of women treated with GCs in the threat of an imminent premature labor do in fact 
continue at term (Davis et al., 2009). Alexander et al. (2012), evaluated cortisol responses in 
acute psychosocial stress in 6-11 year olds, exposed to prenatal GCs, but born at term. The 
results from this study not only revealed higher cortisol responses in the GC group indicating 
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long-lasting effects of the GC treatment, but also showed that the cortisol response more 
pronounced in females, highlighting a sex-specific effect of GCs on modifying the HPA axis 
(Harris and Seckl, 2011). Effects on brain development can be direct as a result in changes in the 
neurogenetic process or due to a reprogramming of the HPA axis which in turn affects key 
developmental processes including neurological maturation. Additionally, full term-born 
children (>37 weeks), exposed prenatally to a single course of BETA, were shown to have a 
reduced birth weight and also reduced head circumference compared to untreated controls (Davis 
et al., 2009). Importantly a recent study used structural magnetic resonance imaging (MRI) to 
evaluate different parameters of cortical development in school age children, which were 
exposed prenatally to GCs and born at term. Interestingly, the results revealed that the GC-
treated group had significant widespread and bilateral cortical thinning. The area mostly affected 
was the anterior cingulate cortex (Davis et al., 2013), which is densely populated with GRs and it 
is tightly related to the pathophysiology of neuropsychiatric and affective disorders (McGowan 
et al., 2009). Along these lines, cortical thinning of the GC-group was associated with 
development of affective problems later in life (Davis et al., 2013). 
 
Collectively the animal and human results point to adverse effects of prenatal GCs on brain 
development. Coming to add to this hypothesis are results from studies on neural stem cells in 
culture either of animal or human origin. Specifically, many groups have shown that GCs and 
specifically DEX which is the focus of this study, can impact multiple stages of neuronal 
development such as the proliferation of neural stem cells and cell cycle progression, cell fate 
and survival (Anacker et al., 2013; Peffer et al., 2014; Samarasinghe et al., 2011). 
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1.4 NEUROGENESIS 
The cerebral cortex is the ultimate locus of human cognition, holding the secrets of reasoning, 
intellect, memory and imagination. The process by which the cortex develops, corticogenesis or 
neurogenesis, is a highly complex sequence of events, tightly controlled at multiple levels of 
organization, both at the temporal and spatial scale. Many of the insights we now have about the 
process of neurogenesis are due to the pioneering work of early developmental biologists such as 
Pasco Rakic, Joseph Altman5 and Shirley A. Bayer. Altman and Bayer, mapped the developing 
brain using birthdating methods and created histological maps that remain valid today6. Pasco 
Rakics’ experiments in monkeys have been instrumental in understanding how embryonic 
neurogenesis in primates proceeds and generates the elaborate cortical structure of the adult 
organism (Rakic, 1988). Moreover, pioneering work by Verne S. Caviness, Jr, Richard S. 
Nowakowski, Tsutomu Takahashi and Robert F. Hevner in the early 90s established the 
foundations for understanding how neuronogenesis takes place from progenitors in the neural 
epithelium of the embryonic mouse. The aforementioned scientists are only a handful of the key 
figures in the arsenal of the neural development area. The field of cortical development is a 
constantly expanding galaxy of discoveries, since the complexity of the processes that govern 
neurogenesis are still poorly understood and still hold many secrets. In this section we provide a 
brief overview of the basic events and key players in the cortical development of the mouse, 
which is the model we use in this study. The reader is referred to the excellent reviews by Kohwi 
                                                 
5 Joseph Altman was the first to show that neurogenesis also takes place in the adult brain, with the 
discovery of the rostral migratory stream (Altman, 1969). 
6 The complete series of studies by Altman and Bayer is available online at: http://neurondevelopment.org/ 
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and Doe (2013); Sun and Hevner (2014) and Greig et al. (2013), for an in depth and detailed 
update on the topic of neural development. 
1.4.1 The neurogenetic process 
The cerebral cortex develops from the rostral most part of the neural tube from neuroepithelial 
stem cells (NEs) lining the surface of the cerebral epithelium. These neuroepithelial cells give 
rise to neural progenitor cells which initiate neurogenic divisions around embryonic day 10.5 
(E10.5) in the mouse. Neuronal production progresses from E11.5 until early E17.5, during 
which the last neurogenic divisions take place (Takahashi et al., 1999). Between E11.5-E17.5, 
neural progenitors divide going through successive cycles of divisions that culminate in a total 
number of 11 complete cell cycles. The cell cycle duration increases with progression of 
neurogenesis, mainly due to an increase in G1 phase, starting with a duration of around 8 hours 
on E11.5 which increases to 18 hours on E16.5 (Takahashi et al.,(Miyama et al., 2001; Takahashi 
et al., 1994; Takahashi et al., 1995; Takahashi et al., 1997). At the beginning of neurogenesis the 
majority of divisions are proliferative and aim in expanding the progenitor pool (Proliferative 
fraction, P, ~1), whereas only a small proportion of divisions, generate neurons (Quitting 
fraction, Q). With the progression of neurogenesis, the rate of proliferation comes to an 
equilibrium with the rate of neuronal production during midgestation (E14.5, P=Q=0.5), whereas 
at the end of neurogenesis Q is ~ 1 (Takahashi et al., 1995; Takahashi et al., 1999). Beyond the 
temporal scale, neurogenesis is also controlled at the spatial scale, with rostral and ventral areas 
of the cortex pacing ahead of caudal and dorsal areas in terms of the time of neuronal production 
initiation (Caviness et al., 2009; Takahashi et al., 1997).  
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1.4.2 Neural progenitors 
The main proliferative population of the neuroepithelium are radial glia cells (RGCs) which are 
progenitor cells derived from the initial population of neuroepithelial stem cells. RGCs reside in 
the ventricular zone (VZ) and are characterized by the expression of specific transcription factors 
such as the nuclear Paired box protein 6 (Pax6), the expression of which is usually used to 
characterize the VZ outline. RGCs, have elongated polarized processes, one on the apical side of 
the ventricular zone and the other impinging on the pial surface (Sun and Hevner, 2014) (Figure 
6B). Through early and past mid-neurogenesis RGCs generate neurons, whereas around E16 and 
onwards, these cells undergo a competence change and start giving rise first to astrocytes and 
then to oligodendrocytes (Campbell and Gotz, 2002; Rakic, 2007; Rakic, 2009). Nascent neurons 
use the radial glia processes as guiding scaffolds to migrate to the cortical plate. With the 
temporal progression of neurogenesis, later born neurons of the upper layers migrate through the 
established early born, deep layer neurons eventually forming the typical six-layered cortical 
plate in an inside-out manner (Greig et al., 2013).  
During the neurogenic phase, RGCs mainly undergo asymmetric divisions and give rise 
to one RGC and one neuron or one intermediate progenitor cell (IPC), (Englund et al., 2005; 
Kohwi and Doe, 2013; Sun and Hevner, 2014). The intermediate progenitor cells (IPCs), form 
the subventricular progenitor zone (SVZ), consist the second progenitor population of the cortex 
and they are characterized by the expression of T-box brain protein 2 (Tbr2) in the nucleus 
(Figure 6C). In contrast to the RGCs which can go through many rounds of division expanding 
their numbers, IPCs are primarily neurogenic with a limited self-renewal capacity. Accordingly, 
IPCs can go two or three rounds of self-renewal divisions, but usually they divide symmetrically 
to two neurons (Pontious et al., 2008). 
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Figure 6. Cortical progenitors and Interkinetic Nuclear Migration  
A-C. The neuroepithelium consists of two types of progenitors, (B) Radial glia cells (RGCs) which 
specifically express Pax6 (green) and (C), Intermediate progenitors (IPCs) which are specifically marked 
with Tbr2 (red). RGCs form the ventricular progenitor zone (VZ) can go many rounds of self-renewal and 
give upon commitment can give rise to IPCs or neurons. IPCs form the subventricular progenitor zone 
(SVZ) are neurogenic and only go two-three divisions before generating two neurons. D. RGCs undergo 
interekinetic nuclear migration (INM), whereby the nucleus of the cell completes S phase in the basal VZ 
and then moves towards the apical VZ through G2 and completes M phase on the apical surface. Then it 
translocates towards the basal side again through G1. (D) is adapted from Sun and Hevner, 2014. 
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1.4.3 Molecular mechanisms controlling cortical development  
The process by which the cortex is built starting from a simple pseudoepithelium to its mature 
form, is highly complicated. The mature cortex comprises by constellations of different cell 
types that form complex neuronal circuits, which are connected with the most intricate patterns 
to achieve maximum precision in information flow within and out of the cortex. To achieve this 
architectural wonder, neurogenesis is highly regulated in the spatial and temporal axis, with 
neuronal production along the rostro-lateral axis preceding neuronal production on the dorso-
caudal axis. Moreover, the fate of the progenitors is regulated on a temporal scale. Specifically, 
cell intrinsic or extrinsic signals impinge upon the progenitors during specific plasticity windows 
to alter the competence of the neural progenitors and thus affect their fate (Kohwi and Doe, 
2013). An example is that deep layer neurons are generated during the early stages of 
neurogenesis whereas upper layer neurons, are generated from mid-neurogenesis and onwards 
(Greig et al., 2013).  
1.4.3.1 Control of cell cycle dynamics and symmetric versus asymmetric divisions 
The cell cycle is a critical factor of progenitor fate since it has been observed from early studies 
(Takahashi et al., 1994; Takahashi et al., 1995; Takahashi et al., 1997; Takahashi et al., 1999) 
that the cell cycle length increases as neurogenesis progresses in parallel with the increase in 
neuronal output. Neurogenic RGCs and IPCs can be distinguished from their counterparts that 
are undergoing proliferative divisions by the expression of the Tis21 protein (Iacopetti et al., 
1999). Using Tis21-GFP knock-in mouse embryos, RGC- and IPC-specific markers, Arai et al. 
(2011) demonstrated by birthdating that neurogenic progenitors have longer cell cycles than self-
expanding progenitors. This happens due to an increase of the G1 phase and shortening of the S 
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phase. Moreover, they showed that in general IPCs have longer cell cycles than RGCs, with 26.5 
hours versus 19.1 hours respectively. Hence, cell cycle dynamics are critical for cell fate and 
differ within and between progenitor types depending on the competence of the cell (i.e., self-
renewing versus neurogenic). Moreover, RGCs and apical progenitors throughout the cortex in 
general, have a characteristic pattern of cell cycle progression (Pilz et al., 2013). The nucleus of 
the cells goes through S phase in the basal aspect of the VZ and then migrates towards the apical 
VZ through G2 to eventually complete mitosis (M phase) on the apical surface (Figure 6D). 
Then it migrates again towards the basal VZ through G1 phase. This phenomenon is called 
Interkinetic Nuclear Migration (INM). Factors that disrupt INM, also affect the fate of RGCs 
(Buchman and Tsai, 2008; Kageyama et al., 2009; Latasa et al., 2009; Murciano et al., 2002; 
Willardsen and Link, 2011). For example, conditional deletion of the proliferation regulator, 
forkhead transcription factor M1 (Foxm1), which is expressed in RGCs but not IPCs, alters the 
synchronization of RGCs and promotes the IP fate (Wu et al., 2014). 
Additionally, Pax6 itself is a master player in cell cycle progression and regulator of the 
switch from proliferation to neuronogenesis (Kohwi and Doe, 2013). Loss of function of Pax6 
results in the RGCs dividing in basal locations, and in an increase in S-phase duration which 
results in smaller cortices due to a compromise in the progenitor pool (Estivill-Torrus et al., 
2002). Interestingly, in Pax6 null cortices, loss of Pax6 function has biphasic effects depending 
on the stage of neurogenesis. Specifically, from early until mid-neurogenesis, Pax6 loss initially 
lead to a decrease in cell cycle duration, increase of asymmetric divisions and precocious onset 
of neurogenesis. Furthermore, from mid-neurogenesis the length of the cell cycle increased due 
to a prolongation in S phase (Estivill-Torrus et al., 2002). These results could be explained partly 
due to the fact that Pax6 exerts regulatory control of the G1 to S phase transition by suppressing 
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cyclin dependent-kinase (CDKs) and cyclin signaling such as CDK6, Cyclin1 and 2. This has as 
a result the repression Rb phosphorylation, which normally promotes cell cycle progression and 
DNA replication (Mi et al., 2013). 
 
Collectively, the fate of proliferating progenitors is highly dependent on the cell cycle dynamics. 
A depletion of the progenitor pool due to a favoring of asymmetrical over symmetric RGC 
divisions or reduction in the progenitor proliferation in general (RGCs and IPCS), ultimately will 
lead to a smaller neuronal output and a smaller cortex. 
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1.5 OBJECTIVES  
This study is fuelled by the combined fact that antenatal use of GCs can lead to detrimental 
effects on neurogenesis, cortical development and the offspring behavior. Yet, the exact role of 
the GR in neural progenitors and in neurogenesis has not been explored in detail. Therefore in 
this study we sought to explore two objectives using the mouse embryo as a model: 
 
Objective 1: Map the temporal and spatial expression of the GR protein in the RGCs and IPs 
of the developing telencephalon, in vivo. 
To our knowledge, a detailed study documenting the spatial and temporal expression of the GR 
protein in the RGCs and IPCs during the time window that neurogenesis is taking place, is 
currently lacking. This applies both for animal models and the human, in which case the results 
from animal models would need to be translated ultimately. Interestingly for the human embryo, 
GR mRNA was detected as early as the first trimester (Condon et al., 1998; Costa et al., 1996). 
In the case of the mouse embryo, GR mRNA was detected in the brain from around E12 (Speirs 
et al., 2004). Nevertheless, neither of these studies focused specifically on the brain nor did they 
examine GR protein expression in progenitors. Considering that progenitor fate and progenitor 
competence varies according to the developmental stage, knowledge of GR’s ontogeny is 
critical to our understanding of how and why antenatal GCs lead to differential effects on the 
developing brain according to the time of exposure (see section 1.3). Therefore the first part of 
this study we sought to map the developmental profile of the GR protein expression in the 
embryonic mouse telencephalon in RGCs and IPCs during the neurogenic window i.e., E11.5-
E17.5. We predicted that GR protein will be present in progenitors from early neurogenesis. 
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Objective 2: Dissect the effects of premature DEX-induced GR activation on the properties of 
neural progenitor cells and cytoarchitecture of the developing cortex. 
During the time window that DEX is used for the management of premature labor, i.e., 24-34 
weeks of gestational age, the human brain is still developing (Kapellou et al., 2006). Specifically, 
the critical window for the development of cortical convolutions lies between 26–36 weeks 
(Dubois et al., 2008), and thus coincides with the window that DEX is used (Figure 7). As 
described in Section 1.3, the effects of prenatal DEX can be variable depending on the dosing 
regimen used in the study and additionally, on the number of courses used. Moreover, a fact that 
to our knowledge has not been highlighted in previous studies, is that during the time that babies 
are exposed to DEX, the endogenous levels of GCs are relatively low and therefore the activation 
of GR from endogenous GCs is expected to be low. The embryo starts to produce cortisol in 
increased quantities during late gestation in preparation for labor while the maternal contribution 
is minimal due to degradation of maternal cortisol by the placental 11βHSD2 (see Section. 
1.1.1.1). Consequently, exposure of the embryo to DEX will result in a premature activation of 
the GR signaling and potentially may disrupt any role that the unliganded GR may have during 
neurogenesis. Therefore in this aim we sought to dissect the effects of a single clinically relevant 
course of DEX on the properties of neural progenitors during mid-gestation (E14.5) in the mouse 
embryo hypothesizing that premature Dex-induced GR signaling will disrupt the proper course 
of neurogenesis by affecting the properties of neural progenitors. Since GC production in the 
mouse embryo initiates around E16, this experimental scheme provides a GC naïve environment 
to explore the effects of premature DEX-induced GR signaling on neurogenesis while being as 
close as possible to the neurodevelopmental effects of the human brain. 
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Figure 7. Timeline of human cortical development from 24 weeks of gestational age until birth. 
A. The cortical surface rapidly increases from 30 weeks and onward, whereas, B. critical cortical 
convolutions arise between 26-36 weeks of gestation, coinciding with the time DEX is prescribed for 
preterm labor. Adapted from and Copyright © of Kapellou et al. (2006). Material used under the terms of 
the Creative Commons Attribution License. 
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2.0  FIRST CHAPTER                                                                                                  
DIFFERENTIAL SUBCELLULAR LOCALIZATION OF THE GLUCOCORTICOID 
RECEPTOR IN DISTINCT NEURAL STEM AND PROGENITOR POPULATIONS                                    
OF THE MOUSE TELENCEPHALON IN VIVO 
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Figure 8. Tsiarli et al., 2013, Issue Cover 
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2.1 INTRODUCTION 
Preface 
Glucocorticoids are given to pregnant women at risk for premature delivery to promote lung 
maturation. Despite reports of detrimental effects of glucocorticoids on telencephalic neural 
stem/progenitor cells (NSPCs), the regional and cellular expression of the glucocorticoid 
receptor (GR) in various NSPC populations in the intact brain has not been thoroughly assessed. 
Therefore in this study we performed a detailed analysis of GR protein expression in the 
developing mouse ventral and dorsal telencephalon in vivo. At embryonic day 11.5 (E11.5), the 
majority of Pax6-positive radial glial cells (RGCs) and Tbr2-positive intermediate progenitor 
cells (IPCs) expressed nuclear GR, while a small number of RGCs on the apical ventricular zone 
(aVZ), expressed cytoplasmic GR. However, on E13.5, the latter population of RGCs increased 
in size, whereas abventricular NSPCs and especially neurons of the cortical plate, expressed 
nuclear GR. In IPCs, GR was always nuclear. A similar expression profile was observed 
throughout the ventral telencephalon, hippocampus and olfactory bulb, with NSPCs of the aVZ 
primarily expressing cytoplasmic GR, while abventricular NSPCs and mature cells primarily 
expressed nuclear GR. Close to birth, nuclear GR accumulated within specific cortical areas such 
as layer V, the subplate and CA1 area of the hippocampus. In summary, our data show that GR 
protein is present in early NSPCs of the dorsal and ventral telencephalon at E11.5 and primarily 
occupies the nucleus. Moreover, our study suggests that the subcellular localization of the 
receptor may be subjected to region and neurodevelopmental stage-specific regulation. 
 
Keywords: glucocorticoid receptor, neural stem/progenitor cells, neurodevelopment, embryo, 
cortex 
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The results of this chapter have been published in Brain Research, 2013. The citation for 
the study follows. Figure 10A of the article (Figure 8 of this document), shown in the 
previous page, was selected for the issue cover. 
 
 
Tsiarli, M.A., Paula Monaghan, A. & DeFranco, D.B.  
Differential subcellular localization of the glucocorticoid receptor in distinct neural stem 
and progenitor populations of the mouse telencephalon in vivo. Brain Res 1523, 10-27 
(2013). 
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In addition to their widespread use as anti-inflammatory agents in adults and children, 
glucocorticoid hormones (GCs)  have become standard antenatal therapy to reduce complications 
of premature delivery since the early 1970s (Liggins, 1969; Liggins and Howie, 1972). GCs 
promote fetal lung maturation and are given to premature babies or to pregnant women at risk for 
premature delivery during late gestation. Synthetic GCs such as dexamethasone (DEX) are 
commonly used in this context and have been shown to reduce respiratory distress syndrome 
development in premature infants (Roberts and Dalziel, 2006). Moreover, DEX is used 
antenatally to reduce virilization of female fetuses suspected of having Congenital Adrenal 
Hyperplasia (Rivkees and Crawford, 2000). The intracellular effects of GCs are primarily 
mediated by the glucocorticoid receptor (GR), a member of the superfamily of nuclear receptors. 
These receptors function as ligand-regulated transcription factors and play important 
physiological roles in organogenesis, metabolism, homeostasis and stress responses (Tang et al., 
2011). 
Despite the benefits of prenatal GCs in reducing the development of respiratory distress 
syndrome and increasing preterm infant survival, accumulating evidence both from animal and 
clinical studies have associated prenatal GC exposure with detrimental effects on brain 
development. For example, in utero exposure to DEX can cause detrimental effects on brain 
morphology such as reduced size and altered layering both in the cortex and the hippocampus 
(Khozhai and Otellin, 2008; Uno et al., 1994). Moreover, prenatal GCs can disrupt the function 
of the hypothalamus-pituitary-adrenal (HPA) axis and thus permanently alter the stress response 
of the offspring (Huang, 2011). Likewise, clinical follow-up studies of children and adults 
exposed perinatally to high levels of GCs, reported cognitive and behavioral abnormalities 
(Lupien et al., 2009; McEwen, 2005; Purdy et al., 2008; Reynolds and Seckl, 2012; Welberg and 
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Seckl, 2001). Furthermore, there are numerous reports linking high levels of GCs in utero with 
cognitive abnormalities and even increased probability of developing schizophrenia (Bombin et 
al., 2012; Huang, 2011; Lupien et al., 2009). On a cellular level, GCs reduce the proliferation 
and alter cell cycle dynamics of both embryonic and adult neural stem/progenitor cells (NSPCs) 
(Heine and Rowitch, 2009; Heine et al., 2010; Kim et al., 2004). The observed effects on NSPC 
properties are the combinatorial result of the genomic actions of the nuclear ligand-bound GR 
and of non-genomic signaling initiated by GC activation of GRs bound on the plasma membrane 
(Samarasinghe et al., 2011). Despite the interest in the actions of GCs in the developing brain 
and their putative link to neuropsychiatric disorders, there is limited information regarding the 
distinct NSPC populations that express GR protein throughout fetal development. In the rat, GR 
mRNA expression was detected as early as E13 in the developing brain (Cintra et al., 1993; 
Kitraki et al., 1996), while in the mouse GR transcripts have been detected as early as E12 in the 
developing telencephalic neuroepithelium (Speirs et al., 2004). These studies however did not 
examine the temporal or cell type-specific expression of GR protein, or its subcellular 
localization. We therefore employed immunohistochemistry to define the spatial and temporal in 
vivo localization of the GR protein in distinct cellular populations of the developing mouse 
telencephalon. Specifically, we focused on the dorsal telencephalon, the future cerebral cortex, 
where cellular abnormalities associated with various neuropsychiatric disorders may first be 
manifested. Our study reveals that GR protein is present in early NSPCs of the dorsal and ventral 
telencephalon at E11.5 and primarily occupies the nucleus. Also, our data show that the 
subcellular localization of GR in NSPCs changes from E13.5 and on, suggesting that the 
subcellular localization of the receptor may be subjected to region and neurodevelopmental 
stage-specific regulation.  
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2.2 EXPRERIMENTAL PROCEDURES 
2.2.1 Animals 
Timed-pregnant CD-1 mice were purchased from Charles River Laboratories (Raleigh, NC) and 
pregnant dams were housed individually and received chow and tap water ad libitum. The day of 
vaginal plug was designated as E0.5. Embryos were collected via caesarian section and were 
fixed in 4% paraformaldehyde (PFA; pH 7.4) and processed through increasing sucrose gradients 
for cryosectioning. Subsequently, brains were embedded in Tissue-Tek Optimal Cutting 
Temperature (O.C.T.) compound (EMS, Hatfield, PA) and sectioned at 20 µm. Animal protocols 
and procedures were approved by the Institutional Animal Care and Use Committee at the 
University of Pittsburgh and adhered to the National Institutes of Health guidelines. At least 8 
animals were used in the E11.5, E13.5 groups and at least 3 animals for the E17.5 and P0.5 
groups.  
2.2.2 Immunohistochemistry 
Immunohistochemistry for GR and other cell-markers were applied as described previously 
(Harrison et al., 2008). Briefly, cryosections were dried for 30 minutes at 46oC or air-dried at 
room temperature for approximately an hour and then washed with 0.1% Triton-PBS. The 
blocking step was performed with 10% heat-inactivated normal goat serum (HINGS, Jackson 
ImmunoResearch, West Grove, PA), for 1 hour at room temperature, followed by three overnight 
incubations at 4°C with the primary antibody, which was diluted in blocking solution. Sections 
were subsequently incubated for 1 hour in the secondary antibody at room temperature, rinsed 
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and counterstained with 4,6-diamidino-2-phenylindole (DAPI). The following primary 
antibodies were used: mouse anti-BuGR2 (1:200, homemade), rabbit anti-Pax6 (1:500, Covance, 
Berkeley, CA), rabbit anti-Tbr2 (1:1000, Abcam, Cambridge, MA), rat anti-Ctip2 (1:500, 
Abcam), chicken anti-Tuj1 (1:200, Neuromics, USA), rabbit anti-Sox2 (1:1000, Abcam), rabbit 
anti-GABA (1:1000, Sigma-Aldrich ,St. Louis, MO), rabbit anti-CB (1:1000, Millipore, CA, 
USA). Secondary antibodies included anti-mouse AlexaFluor 555, anti-rabbit AlexaFluor 488, 
anti-chicken AlexaFluor 647 and anti-rat AlexaFluor 546 (Invitrogen, Carlsbad, CA). 
Fluorescent images were visualized on a Nikon fluorescent microscope, photographed with a 
Photometrics CoolSNAP digital camera and IP Lab software or with an Olympus Fluoview 1000 
confocal microscope (single optical sections and z-stacks, 10X, 20X, 40X or 60X oil immersion, 
single optical section thickness 2.5 μm). Images were adjusted in Photoshop CS4.  
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2.3 RESULTS 
2.3.1 The BuGR2 antibody specifically detects GR protein in the mouse telencephalon. 
GR protein expression was examined in the telencephalon of mouse embryos from E11.5, a point 
when neurogenesis is at early stages (Gotz and Huttner, 2005). For all of the analysis performed 
in this study we utilized a concentrated preparation of the BuGR2 monoclonal antibody 
(Gametchu and Harrison, 1984), which was generated in our laboratory and has been used 
extensively on a variety of cell types (Qi et al., 1989; Samarasinghe et al., 2011). Moreover, 
BuGR2 has been validated as an appropriate GR antibody for in vivo immunohistochemical 
studies (Sarabdjitsingh et al., 2010) and has been used to examine GR expression in the adult 
hippocampus (Fitzsimons et al., 2008). In order to demonstrate the specificity of BuGR2 we 
examined the expression of GR protein within regions of the postnatal mouse brain, where GR 
expression and localization is well established (Usuku et al., 2005). As shown in Figure 1, the 
BuGR2 antibody detected GR in the Cornu Ammonis (CA) areas of the hippocampus, with the 
highest level of expression in the CA1 area and the subiculum (Fig. 9A), in agreement with 
previously published results. In addition, GR was detected in the Dentate Gyrus (DG) (Figs. 9A, 
B, F), as also shown by Patel and Bulloch (2003).  
As additional validation, we compared the BuGR2 staining pattern of the cerebral cortex (Figs. 
9A, C) and DG (Figs. 9A, B, F) to GR expression data from EGFP-Nr3C1 (GR) mice as 
published by the Gene Expression Nervous System Atlas Project (GENSAT) (Gong et al., 2003). 
As shown in Figure 9, the BuGR2 staining pattern in the cortex (Figs. 9A, C) and the DG (Figs. 
9A, B, F) reproduced GR expression in the cortex and the DG of EGFP-Nr3C1 mice (Figs. 9D, 
E, G). Thus, these results show that the BuGR2 can specifically detect GR in histological 
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sections from the mouse telencephalon. 
The GENSAT EGFP data in the postnatal cerebral cortex reveal the expression of GR in neurons 
of the cortex (Figs. 9D and 9E) and the hippocampus (Fig. 9F). However, since EGFP expression 
is driven by the GR promoter, it does not capture the detailed subcellular expression of GR as 
observed with the BuGR2 antibody. Specifically in our study immunohistochemical analysis of 
GR expression using the BuGR2 antibody revealed GR expression both in the cytoplasmic and 
nuclear compartments (Figs. 9A and Figs. 9G-H). 
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Figure 9. The BuGR2 antibody specifically detects the GR protein  
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in the postnatal cortex (A) and the hippocampus (A, B). The pattern of GR expression (red in A and white in the 
grayscale images in B,C,F) as detected by the BuGR2 antibody and visualized in single optical sections of the cortex 
(C) and the Dentate Gyrus (B, F, DG), is similar to the expression pattern of GR in the cortex (D, E) and the DG (G) 
of P7 Nr3c1(GR)-EGFP-reporter mice (Gong et al., 2003; Heintz, 2004). The images are courtesy of the Gene 
Expression Nervous System Atlas (25X, GENSAT, Rockefeller University, http://www.gensat.org/). CA, Area 
Cornus Ammonis; Ctx, cortex 
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2.3.2 Expression of the GR protein in the dorsal telencephalon 
2.3.2.1 GR protein is widely expressed in the E11.5 embryonic body, with high levels of 
expression in the central nervous system. 
GR mRNA has been detected from E9.5 with a peak of fetal expression by E11.5 in the mouse 
(Speirs et al., 2004). We similarly observed widespread expression of the GR protein in E11.5 
mouse embryos (Fig. 10). In particular, non-neuronal areas with prominent GR expression 
included the lung, gastrointestinal track, blood vessels (Fig. 10A) and the developing spinal cord 
(Fig. 10B). In the embryonic central nervous system, GR was widely expressed. Relatively high 
levels of expression were observed in the developing cerebellum (Figs. 10A, C), hippocampus, 
(Figs. 10A), hypothalamus, pituitary and cranial nerves (Figs. 10A, D, E). Importantly, GR 
protein was detected in both the dorsal (future cerebral cortex) and ventral (ganglionic 
eminences) telencephalon (Fig. 10A). In most embryonic tissues at this age, GR appeared to be 
localized predominantly in the nucleus as evidenced by GR expression in the grayscale images 
10B-E.  
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Figure 10. GR is ubiquitously expressed throughout the embryonic body at E11.5.  
(A). Sagittal section throughout an E11.5 mouse embryo, stained with BuGR2 (red) and counterstained 
DAPI (blue). GR is ubiquitously expressed throughout the embryonic body including the spinal cord (A, 
B, Sp), with robust expression levels in some areas such as the cerebellum (C, Cb), the hypothalamus (A, 
Ht), the pituitary (D, Pt) and the trigeminal nucleus (E, TrN). The hippocampus (A, Hip) is one of the 
areas with the highest expression levels of GR in the central nervous system.Ctx, cortex; GE, ganglionic 
eminence; Lu, lung; Sp, spinal cord; H, heart; Eso, esophagus; BV, blood vessels 
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2.3.2.2 GR Protein is Expressed in Radial Glial Cells (RGCs), Intermediate Progenitor 
Cells (IPCs) and Neurons at E11.5. 
In light of the behavioral and cognitive abnormalities observed in children exposed to GCs pre- 
or perinatally, we specifically focused on the developmental expression of GR in the dorsal 
telencephalon beginning on E11.5, an early neurogenesis stage. In the E11.5 dorsal telencephalic 
neuroepithelium, we observed variable GR expression and subcellular localization within distinct 
subregions and NSPC populations (Fig. 11A, B). Specifically, a graded pattern of GR protein 
expression was observed in NSPCs along the apical to basal extent of the neuroepithelium (i.e., 
from the ventricular zone to the pia surface). NSPCs in the apical ventricular zone (aVZ) 
exhibited relatively low to minimal levels of GR protein within their nucleus, while in some 
NSPCs GR was localized in the cytoplasm (Figs. 11C-F). In contrast, NSPCs located in the basal 
ventricular zone (bVZ) expressed relatively high levels of nuclear GR (Figs. 11C-F). Moreover, 
neurons in the preplate layer (PP) exhibited strong nuclear GR localization (Figs. 11C-F). 
At E11.5, the dorsal telencephalon neuroepithelium mainly consists of RGCs, which undergo 
symmetric proliferative divisions and expand the progenitor cell pool. Subsequently, RGCs 
through asymmetric divisions to give rise IPCs and neurons, while IPCs mainly engage in 
terminal neurogenic divisions (Pontious et al., 2008). To determine the pattern of GR expression 
within each of these NSPC populations, we performed double indirect immunofluorescence (IIF) 
labeling with BuGR2 and the RGC-marker Pax6, or BuGR2 and the IPC-marker, Tbr2. While 
GR was expressed in both RGCs (Figs. 11A, D) and IPCs (Figs. 11B, E, F), the subcellular 
localization of the receptor differed between these two progenitor cell types. Specifically, most 
of the Pax6-positive RGCs in the aVZ expressed relatively low levels of GR in the nucleus, with 
more prominent cytoplasmic GR expression (Figs. 11C, D; confocal z-stacks provided in 
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Appendix A. Figs. 35A-C). In contrast, Pax6-positive RGCs in the bVZ expressed relatively high 
levels of nuclear GR (Figs. 11C, D). Nuclear colocalization of GR and Pax6 is most obvious by 
examination of the degree of overlap (yellow/orange) between the BuGR2 stain (red) and of 
Pax6 (green) in Figure 11D and in Sup. Figs. 1A, B. On the contrary, in Tbr2-positive IPCs GR 
was localized within the nucleus (Figs. 11E, F and Sup. Fig. 1D).  
At early stages of neurogenesis, Tbr2 is also expressed in newborn neurons of the PP (Englund et 
al., 2005), as also shown in Figure 11F. Moreover, the PP also hosts pioneer neurons originating 
both from within and outside the dorsal telencephalon (Gotz and Huttner, 2005).  Therefore, to 
distinguish between neurons and IPCs, we performed triple IIF for BuGR2, Tbr2 and the neuron 
specific marker, Tuj1. As shown in Figure 11F, both neurons (Tuj1-positive/Tbr2-positive cells, 
circles; Tuj1-positive/Tbr2-negative yellow arrows) at the bVZ/PP boundary and IPCs (Tuj1-
negative/Tbr2-positive cells, white arrows) expressed nuclear GR (Appendix A. Figs. 35D-F). 
Therefore, in the E11.5 dorsal telencephalon, GR protein was present in the nucleus of the 
majority of RGCs, IPCs and in neurons of the PP. 
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Figure 11. GR is expressed in the nucleus of Radial Glia Cells (RGCs), Intermediate Progenitors 
(IPCs) and early neurons of the E11.5 dorsal telencephalon.  
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Sagittal sections throughout the telencephalon of E11.5 mouse embryos stained with BuGR2 (red) and the 
RGC-marker, Pax6 (A, green), or the IPC-marker, Tbr2 (B, green). GR colocalizes with Pax6- (A, 
orange/yellow) and Tbr2-positive cells (B, orange/yellow), throughout the rostrocaudal extent of the 
telencephalon. (C, D). Single optical section of the area boxed in panel A (similarly, the boxed area in 
panel B is shown in E). Panel C, shows GR expression in grayscale, whereas, panel D shows the same 
section with BuGR2 and Pax6 staining. (E). In IPCs, GR colocalizes with Tbr2 (seen as yellow/orange) in 
the nucleus. (F). Confocal z-stack, of triple immunostaining with neuronal marker Tuj1 (blue), Tbr2 and 
BuGR2, shows expression of GR in early neurons of the E11.5 cortex (yellow arrows, inset F1) and in 
nascent neurons derived from IPCs (circles, Tuj1 (blue)/Tbr2/GR (yellow)-positive cells). Example 
orthogonal projections show GR positive cells with colocalization of Tbr2 and Tuj1 or Tbr2 only. White 
arrows indicate GR expression in IPCs (yellow, Tbr2 only, inset F2). Boxed areas F1 and F2 are shown in 
higher magnification at the bottom of panel F. C-E, single optical sections. Ctx, cortex; LGE, lateral 
ganglionic eminence; MGE, medial ganglionic eminence.  
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2.3.2.3 Differential Subcellular Localization of GR in E13.5 NSPCs 
During mid-neurogenesis (E13.5-E14.5) the IPC population reaches its peak size and forms the 
subventricular zone (SVZ). The upper boundary of the SVZ is identified by the expression of 
Tbr2 (Figs. 12A, B). In addition, during mid-neurogenesis, neurogenic divisions from both, 
RGCs and IPCs generate stellate and pyramidal neurons, which populate the nascent cortical 
plate (Stancik et al., 2010). Double IIF for BuGR2 and Pax6 or Tbr2 on sections of E13.5 
telencephalons revealed that GR is expressed in both progenitor populations (Figs. 12B, C). 
Contrary to the small number (single layer) of RGCs expressing predominantly cytoplasmic GR 
at E11.5, GR was localized mainly within the cytoplasm of the majority of RGCs in the aVZ at 
E13.5, spanning a zone of approximately 3 cell diameters (Figs. 12B, C and 13I, J, arrows). 
Thus, the number of RGCs in the aVZ expressing GR in their cytoplasm increased on E13.5, 
compared to E11.5. Similar to what we observed on E11.5, RGCs in the E13.5 bVZ 
predominantly expressed nuclear GR (Figs. 12B-D, 5E and Sup. Figs. 2A-C), while in Tbr2-
positive cells GR was nuclear (Figs. 12B, D). Triple IIF for BuGR2, Tuj1 and Tbr2 showed that 
GR is nuclear both in mature neurons of the cortical plate (Tuj1-positive/Tbr2-negative, Fig. 4D-
G, arrows) and in nascent neurons (Tuj1-positive/Tbr2-positive, Fig. 12D, circles and Appendix 
A Figs. 36D-F). In Figure 5 we provide a comparison between the subcellular localization of the 
GR protein within NSPCs of the E11.5 telencephalic neuroepithelium (Figs. 13A-D) and in 
NSPCs of the E13.5 neuroepithelium (Figs. 13E-K). Note the distinct cytoplasmic localization of 
GR in NSPCs of the E13.5 aVZ (Figs. 13H, J) which extends approximately 3 cell diameters 
beyond the aVZ, compared to a less prominent cytoplasmic GR profile in E11.5 NSPCs of the 
aVZ (Figs. 13A, D). 
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Figure 12. GR is expressed in the nucleus of RGCs and IPCs of the E13.5 dorsal telencephalon. 
 (A-C).Sagittal section through the telencephalon of an E13.5 mouse embryo stained with BuGR2 (red) 
and Tbr2 (green) (B), or BuGR2 (red) and Pax6 (green) (C). The inset in A, shows the relative anatomical 
position of images in B and C. The immunostaining reveals that GR is expressed in E13.5 IPCs (B), 
RGCs (C), in mature neurons (D-F, Tuj1-positive/Tbr2-negative, arrows) and in nascent neurons derived 
from IPCs (D-G, Tbr2-positive/Tuj1-positive, circles). In the aVZ, GR is primarily cytoplasmic (B, 
arrowheads), whereas in the bVZ/SVZ is primarily nuclear (B, circles). Images B-D, single optical 
sections. Hip, hippocampus, GE, ganglionic eminence, Ctx, cortex, OB; olfactory bulb; MZ, mantle zone; 
CP, cortical plate; SP, subplate; IZ, intermediate zone; SVZ, subventricular zone; VZ, ventricular zone.  
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Figure 13. Differential subcellular distribution of GR in NSPCs of the E11.5 VZ compared to its 
subcellular profile in NSPCs of the E13.5 VZ.  
(A, E) Sagittal sections from an E11.5 and an E13.5 dorsal telencephalon, respectively, stained for 
BuGR2 (red) and counterstained for DAPI. Insets in A and E, show the position of panels B-D and F-H, 
respectively. (A-D) In the E11.5 NSPCs GR is mainly nuclear with the exception of a layer of NSPCs in 
the aVZ (panel D, yellow outlines). (E-H) In the E13.5 aVZ, the number of NSPCs expressing 
cytoplasmic GR is increased, forming a zone which extends up to 3 cell nuclei diameters in the aVZ (E, 
H), whereas, NSPCs of the E13.5 basal VZ (bVZ), contain both cytoplasmic (G, yellow outlines) and 
nuclear GR (G, white outlines). Outlines indicate individual cell profiles. Cells in the cortical plate (F), 
express relatively high nuclear GR. (I-K) High magnification of the E13.5 VZ, where the cytoplasmic GR 
expression in the aVZ is seen in more detail (arrows point to individual cell/nuclei profiles). Note also the 
high nuclear GR content in neighbouring cells that extents into the bVZ. Single optical sections, inset size 
30 μm. 
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2.3.2.4  The Expression of GR is Highest in the Hippocampus and Caudal Cortical Regions 
both at E11.5 and E13.5. 
Neurogenesis in the cortex proceeds in a rostral-high caudal-low gradient (Shimada and 
Langman, 1970). Accordingly, neurons in rostral areas are generated earlier than those of caudal 
areas. Moreover, gradients of morphogenetic and transcription factors are important for 
development, since they are involved in setting borders of brain areas (Caviness et al., 2009; 
Kwan et al., 2012; Rakic, 1988). GR expression appeared to differ along the rostro-caudal axis of 
the developing dorsal telencephalon. This was most apparent when GR expression was 
visualized using a heatmap generated by NIH ImageJ software (Fig. 14) (Schneider et al., 2012). 
Specifically, in low magnification images both at E11.5 (Figs.14A-C) and E13.5 (Figs. 14H, I), 
GR levels were highest in the hippocampal neuroepithelium. In addition the caudal cortical 
neuroepithelium adjunct to the hippocampus expressed relatively higher GR levels in 
comparison to more rostral cortical areas. Side to side comparison of GR expression in high 
magnification confocal images of the rostral and perihippocampal neuroepithelium at E11.5 
(Figs. 14C-G) revealed a smaller number of NSPCs expressing very high GR levels (red) in the 
rostral area (Fig. 14D) compared to the perihippocampal cortical area (Fig. 14E) and the 
hippocampus proper (Fig. 14F). The high GR expression in NSPCs and differentiating cells of 
the hippocampus compared to the cortex, is also seen in a coronal section of the E11.5 
telencephalon (Fig. 14G). Also, GR levels were very high in neurons of the preplate (Figs. 14D, 
E, G, magenta outlines; red cells). Similarly in high magnification confocal images of the E13.5 
telencephalon (Figs. 14J-L), we observed relatively higher GR expression (number of red 
colored cells) in the hippocampal neuroepithelium (Fig. 14L) compared to rostral cortical 
neuroepithelium (Fig. 14J). Moreover, neurons in the cortical plate, expressed high levels of GR 
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compared to NSPCs (Fig. 14J, magenta outline). Thus, the highest expression of GR was 
observed in NSPCs and differentiating cells of the hippocampal area at E11.5 and E13.5. 
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Figure 14. GR expression follows a caudal to rostral gradient in the developing telencephalon.  
Sagittal sections from E11.5 (A-G) and E13.5 telencephali (H-L), in which GR expression is visualized as 
a heatmap generated by NIH ImageJ software (Schneider et al., 2012). The hippocampus (Hip) and the 
adjunct cortical neuroepithelium, express the highest levels of GR both on E11.5 (F, G) and on E13.5 (L). 
(D-G) Confocal z-stacks of a sagittal (D-F) and of a coronal (G) section through the telencephalon on 
E11.5 (C-G) and of a sagittal section on E13.5 (J-L). Insets in C, indicate the anatomical position of 
panels D-F. Preplate (PP) and cortical plate (CP) neurons express high GR levels (D, E, G and J, K 
respectively; magenta outlines). The insets in panels J and K, indicate the anatomical position of confocal 
images J-L. Also, note that the chorioid plexus (ChP) is another area with very high GR levels at both 
ages (E11.5: A-C; E13:5 H, I). Images C-G, J-L, confocal z-stacks. Ctx, cortex; LGE/MGE, lateral and 
medial ganglionic eminence; aVZ/bVZ, apical and basal ventricular zone. 
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2.3.2.5 In the Perinatal Dorsal Telencephalon, GR is Nuclear, Restricted to Specific 
Cortical Layers and Present in Late RGCs and IPCs. 
NSPCs switch from making neurons to glia at late embryonic developmental stages (Kriegstein 
and Alvarez-Buylla, 2009). Therefore to determine if GR protein is also found in glia or 
gliogenic progenitors, we examined its expression during late stages of fetal development i.e., 
E17.5. GR was expressed throughout the dorsal telencephalon (Fig. 15A). In addition, on E17.5 
GR was expressed in the cytoplasm and the nucleus of Pax6-positive RGCs residing at either the 
ventricular or the abventricular surface (Fig. 15C-E). Similar to earlier ages, GR was primarily 
nuclear in IPCs on E17.5 (Figs.15F-H). Moreover we observed that GR is prominently expressed 
in blood vessels (Fig. 15C-E, stars). In the cortical plate at E17.5, GR was expressed at higher 
levels in distinct neuronal populations, i.e. in putative layers IV/V and the subplate (Fig. 15B). 
To verify that the GR-positive cells in the cortical plate are indeed layer V neurons, we 
performed double IIF for BuGR2 and a layer V-specific marker, Ctip2, at P0.5 when layer V is 
distinct. These results revealed that the majority of Ctip2-positive cells expressed nuclear GR. 
Moreover, the relatively high levels of GR in the nucleus of layer V cells (Figs. 15I-L) were 
observed at all rostral to caudal levels.  
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Figure 15. Expression of the GR in the E17.5 cortex.  
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(A) E17.5 horizontal section through the telencephalon, stained for BuGR2 (grayscale). In the inset, the 
anatomical position of panels A and B is indicated by the star (*), while box C indicates the anatomical 
position of panel C. (B) Nuclear expression of GR (red) in cells of putative layers IV/V, VI and in the 
subplate (SP).  (C-E) Horizontal section through the cortex stained for BuGR2 (red), Pax6 (green) and 
counterstained with DAPI. The box in panel C, is shown in higher magnification in D, whereas the boxed 
region in D is shown in E with only BuGR2 and DAPI. (D, E) Outlines in panel D and E indicate 
individual cell profiles, with colocalization of Pax6 and GR (orange/yellow) in RGCs. GR expression in 
blood vessels is indicated by asterisks (*). (F-H) Horizontal section taken from the same anatomical level 
as D, stained with BuGR2 (red), Tbr2 (green) and DAPI (blue). The boxed area represents the images in 
G and H. Expression of GR in IPCs cells is indicated by colocalization of GR (red) and Tbr2 (green) (G, 
yellow nuclei, white arrows), whereas cytoplasmic GR is also evident in the VZ (G, H, yellow arrows). (J, 
K) Coronal section of the telencephalon at P0.5. GR expression in layer V neurons as seen by overlap of 
layer V marker, Ctip2 (green), and BuGR2 (red) (yellow nuclei). C-H, single optical sections. Ctx, cortex. 
Hip, hippocampus, Str, striatum. 
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2.3.3 Expression of GR in the Developing Ventral Telencephalon. 
The glutamatergic cells of the dorsal telencephalon predominantly arise from Pax6- and Tbr2-
expressing NSPCs of the dorsal telencephalic neuroepithelium. In contrast, GABA-ergic 
interneurons are derived from NSPCs in the ventral telencephalon, which consists of the medial, 
lateral and caudal ganglionic eminences (MGE, LGE and CGE respectively). We therefore 
examined the expression of GR protein in NSPCs of the GEs. At E11.5, similar to the dorsal 
telencephalon, GR was expressed in NSPCs of the GEs (Figs. 16A, B) and as shown by 
colocalization of GR with the progenitor marker Sox2 (Fig. 16C). GR was also expressed in 
NSPCs in the corticostriatal boundary (Figs. 16A, B star), an area important for cell migration 
and patterning (Assimacopoulos et al., 2003). In addition, in NSPCs of the GE progenitor zone, 
we observed a mixed pattern of subcellular GR localization. Accordingly, some cells had 
relatively high levels of nuclear GR, while others expressed mainly cytoplasmic GR with 
minimal nuclear staining (Figs. 16A, C). Similarly, in differentiating neurons of the GE we 
observed both nuclear and cytoplasmic GR expression (Figs. 16A, circle). This pattern was 
preserved at all developmental ages examined. In general, NSPCs located on the aVZ surface 
primarily expressed GR in their cytoplasm (Figs. 16A, C insert; arrows pointing to VZ). In 
contrast abventricular NSPCs and differentiated cells primarily expressed GR in their nucleus 
(Figs. 16D, E). To verify that GR is expressed in differentiated cells we used the interneuron 
marker calbindin (CB), and we observed nuclear GR expression in CB-positive cells (Figs. 16D, 
E arrows).  On E13.5, in Sox2-positive NSPCs cytoplasmic GR expression was more 
pronounced in the aVZ. (Figs. 16G,-J), Moreover, GR was also expressed in the nucleus of 
GABA-ergic cells of the E13.5 GEs (Figs. 16K, L). 
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Figure 16. GR is expressed in NSPCs and differentiated cells of the E11.5 and E13.5 Ganglionic Eminences.  
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(A-E) E11.5 and (F-L) E13.5 ganglionic eminences. (A) Single optical section of an E11.5 coronal 
section through the telencephalon, stained with BuGR2 (grayscale). GR is expressed in the lateral 
ganglionic eminence (LGE), in NSPCs of the corticostriatal boundary (CSB, *) and in differentiating cells 
(circle). The boxed region in the inset shows the anatomical position of panel A. (B) Sagittal section of 
the telencephalon on E11.5. GR is expressed throughout the LGE, but in lower levels in cells of the apical 
surface (arrows). (C-E) Sagittal sections through the ganglionic eminence (GE), approximately at the 
level of A. (C) GR is expressed in NSPCs of the GE as seen by colocalization of the NSPC marker, Sox2 
(green) and of BuGR2 (red). Cells on the apical surface primarily express cytoplasmic GR, as also seen in 
the inset of the boxed area. The arrows point to individual cell profiles with cytoplasmic GR expression 
(grayscale). Example orthogonal projections show GR positive cells that also express Sox2. (D-E) GR is 
also expressed in the nucleus of interneurons as seen by colocalization of calbindin (CB, green) and 
BuGR2 (red). The boxed area in D indicates the anatomical position of image E. Arrows in E indicate 
individual cell profiles coexpressing CB and GR. (F) Sagittal section of an E13.5 telencephalon 
containing the LGE, stained for BuGR2 (grayscale). Panel (G) is a single optical section of the boxed area 
in F, showing the LGE and part of the dorsal telencephalon, at higher resolution. GR expression in 
NSPCs of the GE has a mixed nuclear and cytoplasmic profile, but apical NSPCs primarily express 
cytoplasmic GR, similar to NSPCs in the aVZ of the cortex. (H-L) Single optical sections through the 
E13.5 LGE. (H-J) GR is expressed in NSPCs as shown by colocalization (yellow) with the NSPC marker 
Sox2. The boxed region in H is shown in higher magnification in I-J. (K-L) Also, GR is expressed in 
GABA-ergic interneurons, as seen by colocalization of GABA (green) and GR (red). Outlines show 
individual cell profiles. A, C, G-L, single optical sections; D, E, z-stacks. Hip, hippocampus; Ctx, cortex; 
aVZ, apical ventricular zone; bVZ, basal VZ; gVZ, ganglionic VZ; gSVZ, ganglionic subventricular zone. 
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2.3.4 GR is Highly Expressed in the Hippocampus From Early Developmental Stages. 
GCs play a dominant role in learning and memory processes mediated by the hippocampus, both 
in the neonate and the adult brain. In addition, GCs and stress reduce adult hippocampal 
neurogenesis (Gould et al., 1997). Therefore, to evaluate the pattern of GR localization in 
embryonic NSPCs of the developing hippocampus, we examined telencephalic sections through 
the hippocampus from E11.5 embryos. In NSPCs of the E11.5 hippocampus, GR was expressed 
in relatively high levels (Figs. 11B, 17A and B) and in comparison to the rest of the 
telencephalon, the hippocampus had the highest expression levels of GR (Figs. 14C, D, G). 
Interestingly, the relatively high expression of GR extended beyond the Pax6 boundary (Figs. 
17A, B). Similar to the cortex at this age, GR was expressed mainly in the cytoplasm of 
hippocampal NSPCs located in the apical hippocampal VZ, whereas cells located in the SVZ and 
the differentiating zone of the hippocampus, primarily expressed nuclear GR (Fig. 17B). In 
addition, GR was present in Tuj1-positive cells, putatively representing early hippocampal 
pyramidal neurons (Fig. 17C, arrows) and in nascent neurons expressing both Tuj1 and Tbr2 
(Fig. 17C, circles). 
As noted for the E13.5 cortical neuroepithelium, the number of NSPCs in the apical hippocampal 
VZ expressing GR primarily localized in the cytoplasm was increased compared to E11.5 (Fig. 
17D, E arrowheads). In contrast, NSPCs of the hippocampal SVZ, the inner hippocampal mantle 
and putative neurons of the subiculum expressed relatively high levels of GR in their nuclei 
(Figs. 17D, arrows indicate differentiated cells, E, star indicates SVZ area). 
At perinatal stages, i.e., E16.5-E17.5, hippocampal NSPCs mainly give rise to CA1 pyramidal 
cells, while concurrently postmitotic cells are migrating towards their respective laminas in the 
hippocampus (Soriano et al., 1989a; Soriano et al., 1989b).  In E17.5 Pax6-expressing 
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progenitors (Duan et al., 2012), GR was present both in the cytoplasm and nucleus (Figs. 17G-J, 
outlines in I) similar to the cortex, whereas in cells of the subiculum, areas CA1-3 of the Cornus 
Ammonis and the developing DG (Figs. 17G-J), GR was predominantly nuclear. The circled area 
in Figure 17G, delineates the DG which contained GR-positive nuclei (red). Figure 17J shows 
CA1 pyramidal cells that contained relatively high levels of nuclear GR (outlines). 
2.3.5 GR is Highly Expressed in NSPCs Throughout OB Morphogenesis and Delineates 
Specific Cell Layers in the Perinatal OB. 
The formation of OB initiates on E9.5 from cells in the surface neuroepithelium. However, 
neurons destined for the mature OB begin to migrate from the telencephalon around E13.5, 
(Hinds, 1968; Hinds, 1972), a stage where the OB is clearly distinguished as a bud at the rostral 
end of the embryonic telencephalon. Therefore, we examined GR protein expression in Pax6- 
and Tbr2-expressing NSPCs of the embryonic OB from E13.5. At this age, GR showed a 
predominant cytoplasmic localization in Pax6-positive NSPCs with a minimal nuclear 
localization in the developing OB (Fig. 18A). Similar to cortical IPCs, Tbr2-positive IPCs in the 
OB expressed nuclear GR (Figs.18B). The strongest expression of GR at this age was observed 
in differentiating neurons, which contained GR in their nuclei (Figs. 18A, B). This pattern of 
expression persisted until E17.5 where the most prominent expression was observed in the 
nucleus of mitral cells (Figs. 18C, D arrows). In general, the expression of GR in the olfactory 
bulb neuroepithelium, followed the same pattern we had observed for the cortical, ganglionic 
eminences and hippocampal neuroepithelium. Specifically, on E11.5, GR expression in the VZ 
neuroepithelium is mixed, with a small number of cells in the aVZ expressing cytoplasmic GR, 
while others had low levels of GR in their nucleus. In the bVZ and upper layers, GR was 
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predominantly nuclear and was expressed in relatively high levels, while on E13.5 the number of 
NSPCs in the aVZ expressing GR in their cytoplasm was increased. 
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Figure 17. GR expression in NSPCs of the developing hippocampus. 
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(A) E11.5 sagittal section of the hippocampus stained for Pax6 (green), BuGR2 (red) and counterstained 
for DAPI. The boxed area in the inset indicates the position for panels A, B. Panel B shows GR 
expression in grayscale.(C) E11.5 coronal section through the hippocampus immunostained for Tuj1, 
Tbr2 and BuGR2 (single optical section). The boxed area in the inset represents the area shown in panel 
C.  GR is present in NSPCs (A-C) and early neurons (C, arrows) in the hippocampus at E11.5. NSPCs on 
the apical surface primarily express cytoplasmic GR while abventricular cells (A-C) primarily express 
nuclear GR. Circles in C indicate nascent neurons (Tbr2-positive/Tuj1-positive). (D) Single optical 
section of a E13.5 sagittal section stained for BuGR2 (grayscale). GR is expressed in NSPCs on the apical 
surface of the hippocampus (arrowheads) and in differentiating cells of the hippocampal anlagen (arrows). 
Panel E is a magnification of the boxed region in D, showing a primarily cytoplasmic GR expression in 
NSPCs on the apical surface of the hippocampus (arrowheads), whereas abventricular NSPCs primarily 
express nuclear GR (* star). (F) GR expression (BuGR2, grayscale) in the E17.5 hippocampus (horizontal 
section). GR is expressed in areas CA1 and CA3. (G-J) Single optical sections of the hippocampus. Pax6-
positive NSPCs lining the apical surface of the hippocampus express GR (boxed region also shown in 
higher magnification in H). (H) GR staining in Pax6-positive cells lining the top of the CA1 (outlined in 
I) and in pyramidal cells of the CA1 (outlined in J). The newly-forming DG also expresses GR (circle, red 
nuclei). Ctx, cortex; Str, striatum; Hip, hippocampus; Su, subiculum; CA, Cornus Ammonis.  
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Figure 18. Expression of GR in NSPCs the developing Olfactory bulb at E13.5 and E17.5   
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(A) Sagittal section of an E13.5 telencephalon showing expression of GR (red) in Pax6-positive radial 
glial cells. Colocalization of GR and Pax6 is indicated by the yellow color of the cell nuclei. (B) 
Colocalization of GR with Tbr2-positive cells (yellow) in the developing olfactory bulb (OB) at E13.5. 
(C, D) Immunostaining for Pax6 (green) and BuGR2 (red) on a horizontal section of the E17.5 OB. Panel 
D is a single optical section of the OB showing localization of GR in Pax6-positive progenitors of the OB, 
mainly in abventricular positions (yellow nuclei). GR staining is also present in nuclei of the putative 
mitral cell layer (mcl, arrows in D), as well as in Pax6-positive cells of the ventricular surface and the 
outer layer of the OB (yellow, circles). A, B, D: single optical sections. OV, olfactory bulb ventricle. 
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2.4 DISCUSSION 
In this study we demonstrated that GR protein is expressed from E11.5 in RGCs, IPCs and 
neurons of the telencephalic neuroepithelium and is predominantly nuclear within the radial 
extent of the neuroepithelium. Specifically, in the dorsal telencephalon GR was expressed in 
Pax6-positive RGCs, Tbr2-positive IPCs, and in migrating and pioneer neurons of the preplate. 
In a small number of RGCs lining the apical VZ, GR had a predominantly cytoplasmic 
localization, whereas in the basal VZ and the preplate, GR was nuclear. Moreover, nuclear 
expression levels increased in an apical to basal pattern. However, in the E13.5 neuroepithelium 
the population of NSPCs in the aVZ primarily expressing cytoplasmic GR was increased, 
whereas in cells of more basal layers i.e., SVZ NSPCs and neurons, GR gradually progressed 
from a mixed cytoplasmic and nuclear localization, to a predominant nuclear localization in 
differentiating neurons. This neurodevelopmental stage-specific shift from nuclear to 
cytoplasmic localization was also observed in the ganglionic eminences, hippocampus and 
olfactory bulb. Moreover, this differential subcellular profile of GR in NSPCs was maintained 
until perinatal stages i.e., E17.5. 
2.4.1 Nuclear GR in the Absence of GC-Ligand? 
Given that GR has the capacity to shuttle between the nucleus and cytoplasm (Madan and 
DeFranco, 1993), the steady state localization of the receptor is determined by rate-limited 
transport. In tissues of intact animals, many factors could potentially influence the ability of 
physiological levels of GC to drive nuclear import of GR (Vandevyver et al., 2011). Albeit, 
nuclear GR localization in the absence of hormone ligand was observed in cortical pyramidal 
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cells of 3-month old adrenalectomized rats by Pekki et al., (1992). Similarly, we observed 
nuclear GR in NSPCs of the E11.5 neuroepithelium (Fig. 11), a stage where endogenous GCs are 
expected to be minimal. The endogenous production of GCs in the mouse embryo is established 
around E16 in order to promote organ maturation and preparation for the upcoming birth 
(Venihaki et al., 2000). In parallel, at E16, the hypothalamus-pituitary-adrenal axis feedback 
loop becomes active (Reichardt and Schutz, 1996). Therefore, our results suggest that unliganded 
GR may be responsive to region-specific signaling pathways that drive transport into and stable 
accumulation of GR within the nucleus at early neurodevelopmental stages. 
2.4.2 GR Expression in NSPCs and Subcellular Expression 
Our results show that expression of GR within the radial extent of the neuroepithelium changes 
with development. Specifically, on E11.5 a small number of RGCs in the aVZ primarily 
expressed cytoplasmic GR, whereas the rest of the NSPCs expressed low levels of nuclear GR in 
apical areas but higher levels in basal areas. On E13.5, the number of RGCs primarily expressing 
cytoplasmic GR was increased in the dorsal cortex and throughout the telencephalon from E11.5 
to E17.5. Nevertheless, GR remained nuclear in IPCs irrespective of their position in the 
neuroepithelium. Therefore, cytoplasmic localization of GR appears to be specific for embryonic 
RGCs and NSPCs adjacent to the ventricle. It is possible that specific growth factors present in 
the cerebral spinal fluid limit GR nuclear localization.  
In the adult hippocampus, GR colocalizes with the stem cell protein nestin, both in vivo and in 
vitro (Garza et al., 2011; Reimer et al., 2009). Nestin has a regulatory role on the function of GR, 
and specifically a nestin/vimentin network maintains the unliganded GR in the cytoplasm and is 
associated with an increased proliferative capacity. Since Pax6-positive radial glia in the aVZ 
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express high levels of nestin in contrast to their IPC progeny in the bVZ/SVZ, from which only a 
minimal proportion expresses nestin on E14.5 (Dahlstrand et al., 1995; Englund et al., 2005), it is 
tempting to speculate that nestin may also have a similar role in the subcellular GR localization 
we observed. Interestingly, Fitzsimons et al. (2008) showed that in adult hippocampal NSPCs, 
nuclear translocation of GR is controlled by cytoskeletal components, making this a plausible 
mechanism operating in the embryonic NSPC niche.   
2.4.3 A Role for Unliganded GR in NSPCs? 
Unliganded GR was recently shown to be necessary for induction of the tumor suppressor  gene, 
BRCA1, in nonmalignant mammary cells (Ritter et al., 2012). GR interacts with the promoter of 
BRCA1 only in the absence of GCs, while exposure to hormone inhibits this interaction. BRCA1 
is expressed in the VZ of the E11.5 mouse telencephalon (including the hippocampal and 
olfactory bulb primordial) and regulates the proliferation of early progenitors in the E11.5 VZ 
(Pulvers and Huttner, 2009). Therefore, the unliganded GR may regulate the survival and/or 
proliferation of VZ progenitors in the dorsal telencephalon through an analogous influence on 
BRCA1 gene expression or of other transcription factors.   
Phosphorylation of GR is a key mechanism for controlling the receptor’s activity and can 
influence the transcriptional targets of the receptor (Galliher-Beckley and Cidlowski, 2009). 
Interestingly, ligand-independent GR phosphorylation by p38 MAPK occurs in vitro on human 
and rat GR (Galliher-Beckley et al., 2011) and increases the association of GR with its cofactor 
14-3-3zeta to change the transcriptional response to hormone. p38 MAPK and other components 
of the JNK pathway are highly expressed in the intermediate zone (IZ), preplate and cortical 
plate of the developing mouse dorsal telencephalon, sites where we observed a predominant 
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nuclear GR localization. Constitutive expression of an upstream activator of the JNK pathway, 
MUK, from E13, arrests the migration of newborn neurons out of the SVZ/IZ boundary on E16 
(Hirai et al., 2002), an effect associated with the microtubule network. Therefore region and 
neurodevelopmental stage-specific activation of MAPKs that target GR could ultimately 
influence the subcellular localization of the receptor and its association with unique targets that 
could differentially impact NSPC function.    
2.4.4 GR and Perinatal GC Use 
While GCs have been used for decades in perinatal medicine, evidence from animal and clinical 
studies suggest a need to re-evaluate this usage. Early in vivo studies with the rhesus monkey 
from Uno et al., (1990, 1994),   demonstrated that prenatal DEX exposure can have deleterious 
effects on the developing telencephalon architecture, such as reduced cortical size and disrupted 
lamination of the cortex and hippocampus. Similar results have been obtained in murine models 
(Fukumoto et al., 2009; Heine and Rowitch, 2009; Khozhai and Otellin, 2008). In humans, 
antenatal GCs have been linked with reduced head circumference and cortical convolution (Modi 
et al., 2001; Thorp et al., 2002). In addition, prenatal stress has been linked to attention and 
learning deficits, anxiety and depression in the offspring (Mesquita et al., 2009). Therefore, when 
studying the effects of GCs on the developing brain, knowledge of the precise spatial and 
temporal expression of GR protein is essential to ascertain the molecular basis for potential 
detrimental effects of antenatal GCs. For example, we observed that GR is highly expressed in 
the Ctip2-positive subpopulation of layer V neurons of the cortex.  These cells are subcerebral 
projection neurons which extend their axons to the basal ganglia, diencephalon, midbrain, 
hindbrain, and the spinal cord (McKenna et al., 2011). Hence, they act as efferents for top-down 
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information transmission, from the cortex to lower order processing centers. Furthermore, we 
observed that GR expression was high throughout the rostrocaudal extent in layer V and in 
frontal regions of the cortex, including the prefrontal cortex. Neuronal circuit malfunction in 
these areas and especially in the prefrontal cortex has been associated with the evolution of 
neuropsychiatric disorders of which the root is thought to be in the neurodevelopmental period 
(Tekin and Cummings, 2002). Particularly important in relation to neuropsychiatric disorders is 
the presence of GR in NSPCs of the GEs. The GEs give birth to interneurons, which populate the 
telencephalon, hippocampus and olfactory bulb. Interneuronal function and stress i.e., increased 
in utero GC levels have been linked with the risk of developing schizophrenia (Czeh et al., 
2005).  
In summary, we have shown that GR protein is present in early progenitors of the dorsal and 
ventral telencephalon at E11.5 and primarily occupied the nucleus of the cells. Moreover, the 
region-specific expression of GR protein in the developing telencephalon suggests that 
subcellular localization of the receptor may be subjected to region and neurodevelopmental 
stage-specific regulation.  The results from our study may provide a basis to better understand 
the effects of GCs on telencephalic development both in vivo and in vitro. Furthermore, the 
presence of GR in the nucleus of most NSPCs and its dynamic expression within the 
neuroepithelium raises a question about the precise role of GR in NSPCs, particularly in the 
absence of endogenous GC production. A more in depth understanding of GR’s expression 
dynamics in the developing brain may provide insights relevant for the limitation of potential 
neurologic side effects of GCs, while maintaining and enhancing their beneficial potential during 
pregnancy.  
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3.0  SECOND CHAPTER                                                                                             
PREMATURE ACTIVATION OF GR DURING MIDGESTATION ALTERS                  
NEURAL PROGENITOR PROLIFERATION IN A CELL CYCLE                                                                
DEPENDENT-MANNER AND IMPAIRS CORTICAL DEVELOPMENT 
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3.1 INTRODUCTION 
Synthetic glucocorticoids (sGCs) have been used now more than half a century in preterm 
medicine mainly in the case of an imminent threat for preterm labor. GCs are naturally organ 
growth promoting hormones and in this case are used to help the maturation of the fetal lungs 
and reduce the incidence of respiratory distress syndrome, periventricular leukomalacia and of 
intraventricular hemorrhage (Braun et al., 2013; Pang et al., 2012; Tegethoff et al., 2009). 
Nonetheless, approximately 25-30% of pregnancies at risk for preterm labor treated with sGCs 
reach term (Davis et al., 2009).  Dexamethasone (DEX), a potent sGC, is the suggested GC to be 
used for preterm labor between 24-34 weeks, according to the WHO guidelines. DEX is resistant 
to 11β-HSD2 placental degradation and therefore accumulates at much higher levels in fetuses. 
During the critical human gestational ages of 24-34 weeks allowed for DEX treatment, and 
especially from 30 weeks and onwards, the embryonic brain undergoes a dramatic spur of 
development, mostly in terms of cortical surface expansion and development of the elaborate 
gyrification pattern of the cortex (Kapellou et al., 2006). Between weeks 30-32, the fetus starts to 
produce de novo GCs which stimulate lung surfactant production in preparation for labor (Braun 
et al., 2013). Otherwise, before this period the levels of endogenous GCs (i.e. cortisol in humans) 
in the fetus are relatively low, due to minimal de novo production and minimal contributions 
from the mother because of efficient cortisol metabolism by placental 11ß-HSD2 (Ishimoto and 
Jaffe, 2011).  Thus during the period that DEX is typically given to pregnant women, the brain is 
considered a GC-poor environment, suggesting that interaction of DEX with the brain GR will 
be premature. Accumulating evidence both from animal and clinical studies are revealing that 
exposure to sGCs during this critical fetal period may result to changes in cortical development 
which can be permanent and may manifest postnatally as cognitive, behavioral and affective 
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problems (Huang, 2011; Lupien et al., 2009; McEwen, 2005). Studies in different animal models 
such as rodents, sheep (in which the time of fetal lung development mimics closely the human) 
and primate, suggest that sGCs can affect cortical, cerebellar and hippocampal development 
(Khozhai and Otellin, 2008; Sundberg et al., 2006; Uno et al., 1990; Uno et al., 1994) impair 
cerebral myelination and change the normal course of development of different neurotransmitter 
systems such as serotonin and dopamine (Kreider et al., 2006). Moreover, through premature 
initiation of the GC-GR signaling cascade, the function of the HPA axis is altered, leading to a 
predisposition for a multitude of medical conditions ranging from metabolic, cardiovascular to 
affective and even neuropsychiatric problems (Huang, 2011). Accumulating results from 
children that had been prenatally exposed to sGCs but born at term, show that GC exposure may 
lead to reduced birth weight and head circumference, and importantly changes in the cortical 
structure that are associated with the development of affective problems (Braun et al., 2013; 
Davis et al., 2013). Therefore, these results point to a need for in-depth analysis of the role of the 
GR in cortical development and call for an understanding of the effects of activating prematurely 
the GR-GC signaling cascade.  
 In this study we sought to examine the effects of premature activation of the GR-GC 
signaling on cortical development by specifically dissecting the cell-specific effects of prenatal 
DEX exposure on the different neural progenitor populations of the cortex and on the 
development and cytoarchitectural composition of the developing cortex. To our knowledge this 
is the first study using this approach, since none of existing studies has focused on this level of 
detail on the effects of the premature activation of the DEX -GR signaling in the cortical 
progenitor cell biology and on cortical cytoarchitecture. Specifically, we used a single course of 
DEX at a clinically relevant dose in E14.5 mice (midgestation) to examine the effects of a 
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premature GR activation on the proliferation of RGCs and IPCs. My results show that DEX-
induced GR activation shifts the balance towards neuronogenesis at the expense of proliferation 
by primarily affecting RGC proliferation. This effect was S-phase dependent, since in RGCs that 
were in S-phase, DEX promoted an expansion of the neurogenic pool and in S-phase IPCs, DEX 
promoted neurogenic divisions. In non-S phase RGCs DEX exposure promoted an IPC fate. 
Within this context, BrdU birthdating 72 hours following the DEX injection on E14.5 (E17.5), 
revealed that a higher proportion of BrdU cells was located in the cortical plate and a smaller 
proportion was found in the progenitor domain of DEX-treated embryos, compared to the 
controls. Moreover, DEX exposed animals had increased numbers of neurons in all layers of the 
cortex (LVI-II) but had a smaller cortex in terms of cortical thickness and surface and an 
impaired brain growth overall as revealed by reduced brain to body weight ratio. These data 
support the hypothesis that DEX promoted neuronogenesis at the expense of proliferation. 
Collectively our results indicate that premature DEX-induced GR signaling during mid-
neurogenesis, alters NPC proliferation and leads to long-term changes in the cortical 
cytoarchitecture highlighting a critical role for the unliganded GR in neural development which 
is disrupted in the presence of DEX. 
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3.2 EXPERIMENTAL DESIGN 
3.2.1 Animals 
Timed-pregnant CD-1 mice were purchased from Charles River Laboratories (Raleigh, NC) and 
pregnant dams were housed individually and received chow and tap water ad libitum. The day of 
vaginal plug was designated as E0.5. Animal protocols and procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Pittsburgh and adhered to the 
National Institutes of Health guidelines.  
3.2.2 Tissue Preparation and Processing  
Embryos were collected via caesarian section and were fixed in 4% paraformaldehyde (PFA; pH 
7.4) and processed through increasing sucrose gradients for cryosectioning. Subsequently, brains 
were embedded in Tissue-Tek Optimal Cutting Temperature (O.C.T.) compound (EMS, 
Hatfield, PA) and sectioned at 20 µm. Alternatively for the production of paraffin sections, 
embryos were fixed overnight at 4oC in fresh SEARS solution (30% formalin; 10% glacial acetic 
acid; 60% pure ethanol) and processed for paraffin embedding and sectioned at 10 μm. For each 
experimental condition at least 3 animals were used. 
3.2.3 Immunohistochemistry 
Immunohistochemistry for cell-markers was applied as described previously (Tsiarli et al. 2013). 
Briefly, cryosections were dried for 30 minutes at 46oC or air-dried at room temperature for 
approximately an hour and then washed with 0.1% Triton-PBS. Paraffin sections were warmed 
at 56oC and then de-paraffinized and rehydrated through a series of xylene and decreasing 
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concentrations of ethanols (100%, 95%, 70%), rinsed with water and washed with 0.1% Triton-
PBS. Antigen retrieval was performed with same-day-made 1X sodium citrate buffer (2.194 gr 
sodium citrate in 1 L PBS, pH 6.0) by microwaving for all staining combinations. After reaching 
room temperature, the sections were blocked with 10% heat-inactivated normal goat serum 
(HINGS, Jackson ImmunoResearch, West Grove, PA), for 1 hour at room temperature, followed 
by three overnight incubations at 4°C with the primary antibody, which was diluted in blocking 
solution. Sections were subsequently incubated for 1 hour in the secondary antibody at room 
temperature, rinsed and counterstained with 4,6-diamidino-2-phenylindole (DAPI). Table 3.1 
describes the list of primary and secondary antibodies used in this study. Fluorescent images 
were visualized with an Olympus Fluoview 1000 confocal microscope (single optical sections 
2.5 um thickness, 40X oil immersion) or a on a Nikon fluorescent microscope, photographed 
with a Photometrics CoolSNAP digital camera and visualized with the NIS elements software 
(Nikon). Images were adjusted in Photoshop CS5. 
3.2.4 DEX and BrdU injections 
Timed-pregnant mice at E14.5 were intraperitonealy (ip) exposed to a single course of DEX (0.4 
mg/kg) or vehicle. Immediately after, animals were given a single ip pulse of BrdU (0.5 mg/kg). 
Embryos were collected by cesarean section, sacrificed by decapitation and studied after 24 or 72 
hours after DEX injection (E15.5 and E17.5 respectively).  
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3.2.5  Fluorescence-Activated Cell Sorting (FACS) Analysis 
Dorsal cortex tissue was dissected in cold PBS following 24 hours of DEX and BrdU exposure. 
The tissue was dissociated in PBS using a 200 μl pipette and gentle aspiration, filtered through a 
40 μm filter and pelleted at 200 rpm for 5 minutes, at 4°C. Following this step, cells were 
washed with cold PBS and while vortexing 70% Ethanol in PBS was added drop-wise to avoid 
clumping and cells were left to fix for 30-60 minutes at 4°C. After fixation, samples were 
pelleted as above and the ethanol was carefully washed by cold PBS. Antigen retrieval was 
performed by adding distilled water and then dropwise 12N HCL until diluted to 2N and left for 
30 minutes in room temperature (RT). After antigen retrieval, cells were pelleted and washed 
with PBS and then blocked with 10% HINGs for 20 minutes in RT. Then samples were stained 
with BrdU-rat in 10% HINGS (1:50, Abcam) approximately for 30 minutes in RT, pelleted, 
rinsed with PBS and incubated with Alexa 647 anti-rat (1:1000, Invitrogen), and after with DAPI 
to stain DNA. Flow cytometry, was performed at the University of Pittsburgh Immunology Flow 
Cytometry Core, using an LSRFortessa cytometer. Parameter adjustment and analysis of the raw 
FACs data was performed by Dr. Albert D. Donnenberg and Mr. Michael Meyer at the Cell 
Cytometry Facility of the University of Pittsburgh Cancer Institute (UPCI) which is supported in 
part by award P30CA047904.  
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3.2.6 Quantification and Statistical Analysis 
All statistical data are presented as mean ± SD. Data were tested for statistical significance by 
the two-tailed Student's t test using the GraphPad Prism software 6 (©2014 GraphPad Software, 
Inc., CA, USA), at a significance level of 0.05, using an n ≥ 3 per experimental condition.  
 
             Table 3. List of Antibodies and Dilutions 
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3.3 RESULTS 
3.3.1 A single exposure to DEX during mid-gestation (i.e. E14.5) alters brain development 
when assessed at E17.5. 
Several clinical studies examining the effects of antenatal GCs given for preterm labor, have 
reported adverse effects on birth weight, head circumference and later neurological development 
of the offspring. These reports also include term-born children that were exposed prenatally to 
GCs (Davis et al., 2009; Davis et al., 2013; Khalife et al., 2013) who therefore do not have 
complications associated with premature birth and neonatal intensive care.  These results have 
been replicated in different animal models such as in the mouse, rat, monkey and sheep (Braun et 
al., 2013; Tegethoff et al., 2009). Nevertheless, due to the fact that some studies use multiple 
courses of DEX and at different developmental stages, some results are conflicting.  In order to 
identify the biological consequences of a single course of DEX in a clinically relevant dose on 
brain development, we exposed midgestation (E14.5) embryos to 0.4 mg/kg DEX and collected 
the embryos 72 hours after the injection (E17.5). Our experimental setting is unique due to two 
reasons, firstly because we are using a single exposure to DEX which allows us to examine the 
“baseline” effects of DEX on cortical development, without having the ambiguity of multiple 
injections. Secondly and most importantly, these settings mimic the human fetal period during 
which DEX is administered, where endogenous levels of GCs are low. Similarly, E14.5 mouse 
embryos have minimal levels of endogenous GCs. Thus this allows us to dissect the effects of a 
premature DEX-induced activation of GR signaling on neurogenesis and cortical development. 
For all the injections in these study, the timed-pregnant dams were injected between 
10:00-11:00 am and the embryos were collected after the selected time window again between 
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10-11:00 am. Initial experiments used E18.5 embryos that have a more mature cortical plate, but 
since this is close to parturition in the mouse, a number of dams were giving birth prior to our 
planned collection of embryos. Therefore we examined DEX effects at E17.5 and collected 
controls and treated embryos by caesarean section.  To evaluate brain growth following 72 hours 
after DEX exposure, we analyzed the brain to body weight ratio (BBWR), which provides an 
indirect index of brain growth. The total weight of the embryos was first recorded, followed by 
the weight of the whole brain. In agreement to findings of other studies and to our hypothesis 
that DEX would alter brain growth, in DEX treated animals the BBWR was reduced compared to 
the controls (Fig. 19A). The reduction was evident even after controlling for litter size (Litter A: 
ncontrol = 13, BBWR=; nDEX = 6; Litter B: ncontrol = 11; nDEX = 12). Therefore, an average 
reduction of BBWR was observed for both DEX litters at 15% over the controls (pooled results 
from two litters). Interestingly, in both experiments, the body weight was slightly but 
significantly increased (Appendix B, Figure 37; mean (g) ± SD; Litter B: Control 1.2 ± 0.075; 
DEX 1.4 ± 0.086; p< 0.0001), suggesting that DEX differentially affected the body growth 
versus the brain. Despite this fact, normalized BBWR was reduced, indicating that the brain does 
not grow proportionally to the body when it is exposed to DEX. This result suggests that a single 
course of DEX during E14.5 leads to an impairment in body and brain growth. 
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Figure 19. A single DEX course on E14.5 impairs brain growth by E17.5 as evaluated by the Brain to Body 
Weight Ratio (BBWR).  A. BBWR for two separate groups of litters, of different litter sizes, revealed that 
DEX effects are independent of litter size. BBWR mean ± SD; Student’s t-test, Littter A: ncontrol = 13, nDEX 
= 6, Control_a BBWR= 0.063± 0.0078 (analyzed 6 animals), DEX_a BBWR= 0.053 ± 0.0048; p< 0.05; 
Litter B: ncontrol = 11; nDEX = 12 (analyzed 7 per group); Control_b BBWR 0.065± 0.0050, DEX_b 0.058± 
0.0033, p< 0.05. B. Pooled data from both litters, Control BBWR 0.064± 0.0063, DEX BBWR 0.056 ± 
0.0049, p <0.001. 
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3.3.2 Activation of GR-GC signaling by a single course of DEX on E14.5 causes a 
reduction, both in the radial and lateral expansion of the cortex after 72 hours. 
Cortical development proceeds in the radial dimension resulting in a progressive increase in 
cortical thickness (radial expansion), and on the lateral dimension (lateral expansion) resulting in 
an expansion of the cortical surface. During the 24-34 week time-window when DEX is 
administered to pregnant women, the brain undergoes dramatic development both in terms of 
cortical surface increase and in terms of increasing complexity in the cortical folding pattern 
(Dubois et al., 2008; Kapellou et al., 2006). Not surprisingly, antenatal GCs have been reported 
to be associated with a reduction in cortical surface and cortical convolution complexity (Modi et 
al., 2001), and also with reduction in cortical thickness, even in term born children (Davis et al., 
2013). Therefore it seemed plausible that the impairment of brain growth we observed in DEX-
treated embryos may be the result of an underlying impairment in cortical development. 
Following the method described by Pulvers and Huttner (2009), we analyzed both the cortical 
surface and cortical thickness in Nissl stained E17.5 coronal sections of E14.5 DEX-treated and 
control embryos (Figure 20). Indeed, in DEX-treated animals both the cortical surface was 
reduced and cortical thickness were significantly reduced by 15% and 10% respectively (Figure 
20).   
 
 
 
 
 
 92 
 
Figure 20. A single exposure to DEX on E14.5 impairs cortical development as seen after 72 hours. A, C. 
DEX exposure on E14.5 induces an impairment in the lateral expansion of the cortex i.e., cortical surface, 
by E17.5 (pink line). Mean ± SD, ncontrol = 5; nDEX l= 6; Control 763 ± 36, DEX Control 667 ± 18, p < 
0.001. B, D. Also the cortical thickness (yellow line) in DEX-treated embryos is reduced Control 120 ± 
3.8, DEX Control 105 ± 8.3, and p < 0.01. 
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3.3.3 DEX-induced GR signaling during mid-gestation promotes supernumerary neuron 
production in deep- and upper-cortical layers. 
Since both cortical surface and cortical thickness are a reflection of cortical cytoarchitecture 
integrity (Fischl et al., 2004), we wondered if the impaired cortical growth of the DEX-treated 
embryos could be the result of altered cortical lamination. To evaluate this hypothesis we used 
specific molecular markers to individually label layers VI-II and the subplate (SP). Initially we 
evaluated deep layers VI and V, since at E14.5, when the embryos are exposed to DEX, layer V 
production is at its maximal rate, whereas, layer VI production is being completed (Takahashi et 
al., 1999). Upon initial observations the spatial ordering of the deep cortical layers VI (Tbr1+) 
and V (Ctip2+) appeared to be preserved (Figure 21). Therefore DEX exposure did not disturb 
the process by which these layers are specified and established. We observed a similar situation 
in the case of upper layers IV (Satb2+) and II/III (Cux1+), whereby the cells that already 
migrated in the cortical plate were at their expected positions whereas, many were still migrating 
though the intermediate zone and the deep layers (Figures 21C-D’). Therefore, DEX treatment 
did not affect the spatial positioning of the cortical layers. 
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 Figure 21. DEX exposure on E14.5 does not affect cortical layer positioning of postmitotic neurons in the 
E17.5 cortical plate. A-D. The positioning of the layers is relatively similar in the control embryos versus 
A’-D’, the DEX-treated embryos. Nevertheless, close inspection of the staining patterns of each marker in 
the cortical plate especially indicates DEX may have promoted differences in the abundance for each 
marker. Tbr1 deep layer VI (LVI) and Subplate (SP) marker; Ctip2: LV marker; Satb2: LIII-IV marker; 
Cux1: LII/III marker. PZ, progenitor zone, Scale bar 50 μm. Embryo image source Zhang Lab, Harvard. 
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Nevertheless, visual inspection of control and DEX-treated cortical sections co-stained with 
DAPI and laminar markers such as Satb2 (Figures 21B -B’) and/or with laminar markers such as 
Satb2/Ctip2/Cux1 (Figures 21C-D’), suggested that the number of neurons may differ between 
the two groups. Therefore, as a first approach to evaluate this observation, we counted the 
number of DAPI stained cells within the cortical plate (including the subplate). Interestingly, 
despite having a thinner cortex, DEX-treated embryos also had an increased number of DAPI 
cells in their cortical plate (Figure 22). This result prompted the question of whether this increase 
was due to a contribution from a specific layer population. On the day of DEX exposure, i.e., 
E14.5, the majority of LVI cells is already born and LV is reaching the climax of its birth rate. 
Also, the generation of upper layers II/IV is steadily increasing from E14.5 onwards (Takahashi 
et al., 1999). Therefore the most likely candidate to have contributed the increased number of 
DAPI cells in the cortical plate was layer V, then followed by upper layers II/IV. Hence, with the 
help of the laminar markers, we quantified the number of neurons that correspond in each layer 
within the cortical plate, including deep layer VI and the SP populations (Tbr1+) in the analysis. 
As expected, DEX-treated cortices had a large increase in the number of LV neurons, which 
amounted to a 64% compared to the control values (number of Ctip2+ cells), and an increase in 
Satb2+ (32% compared to controls), as well as Cux1+ neurons (43% compared to controls, 
Figure 23B). On E17.5, many of the neurons of upper layers LIV-II are still migrating as seen in 
Figures 23A and C, therefore the above percentages are more likely underestimations. Therefore, 
DEX-induced GR signaling initiated on E14.5, resulted in a global effect on the generation of 
neurons, without having a subtype-specific effect, since neurons in all cortical layers, including 
deep layer VI were increased. 
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Figure 22. DEX exposure on E14.5 results in higher number of cells within the cortical plate. A, B.  In the 
DEX-treated cortices (B) the number of neurons increases by 24% compared to the controls (A). C. 
Number of DAPI cells in the cortical plate ± SD, Student’s t-test, n= 4; Control 826 ± 29, DEX 1021 ± 
44, p < 0.01. 
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Figure 23. A single exposure to DEX on E14.5 induces a supernumerary production of neurons in all layers 
including deep layer VI on E17.5. A. Neuronal production of Layer V (LV) reaches its maximum on E14.5 
when DEX is given, while the production of upper layers LII-IV is steadily increasing. B. DEX exposure 
causes an increase in the production of neurons in all layers with maximum effect on LV, which increases 
by 64% compared to the control. Number of Layer Marker-positive cells ± SD, Student’s t-test, nControl=3, 
nDEX = 4; Tbr1: Control 322 ±21; DEX 387±39, p< 0.05; Ctip2: Control 253 ± 23, DEX 415± 33, p< 
0.001; Satb2: Control 581 ± 10, DEX 767 ± 47, p <0.01; Cux1: Control 371 ± 52, DEX 530 ± 21, p < 
0.01). C. Ctip2+ LV neurons in the DEX –treated cortices are more and occupy a greater area (outlined 
region). Scale bar 50 μm.   
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3.3.4 BrdU birthdating on E14.5, reveals a higher proportion of cells that have migrated 
in the cortical plate at the expense of progenitor-self renewal in DEX-treated embryos. 
The fact that following 72 hours of a single DEX exposure on E14.5, the cortex contains more 
neurons albeit is reduced in thickness prompted the question of whether this was the result of 
altered proliferation of the progenitors that generate these neurons. To address this possibility we 
injected E14.5 mice with DEX and also gave them a pulse of BrdU to label the proliferating 
population going through S-phase. Then we analyzed the number of BrdU+ cells in the cortical 
wall after 72 hours. This strategy allowed us to trace the number and position of the progeny of 
NSPCs that were in S-phase during the time that DEX induced GR signaling. Interestingly, DEX 
treatment at E14.5 caused a 39% increase in the number of BrdU labelled cells occupying the 
cortical wall by E17.5 (Figure 24). Visual inspection of the BrdU pattern throughout the cortical 
wall suggested that the distribution of the BrdU+ cells differed between controls and DEX-
treated embryos (Figure 24).  Thus, to determine whether this pattern reflected a change in the 
post-mitotic output of the NSPCs following DEX exposure, we evaluated the proportional 
distribution of the BrdU+ cells throughout the functional zones of the cortex i.e., the cortical 
plate (CP), subplate (SP), intermediate zone (IZ) and the progenitor zone (PZ). In agreement to 
the increase in neurons of all layers that we had observed previously, DEX-treated cortices 
contained a greater proportion of BrdU+ cells in the CP (+19%) (Figure 25B) specifically in LV-
II (Figure 25C), but had a smaller proportion of BrdU+ cells within the PZ (-15%) and the IZ (-
16%) (Figures 25B and C).  
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Collectively, these results suggest that DEX-induced GR signaling on E14.5, promoted 
progression of NSPCs through the S-phase at E14.5 which was reflected in an increased number 
of BrdU+ cells. This effect is translated as increased neurogenesis that occurs at the expense of 
self-renewal of progenitors by E17.5, since a significantly higher proportion of BrdU+ cells 
occupied the CP and a lower proportion resided in the PZ of the DEX-treated embryos. 
 
 
 
 
 
Figure 24. NSPCs exposed to a single course of DEX on E14.5, generate higher numbers of progeny as seen on 
E17.5. A-C. S-phase NSPCs that were exposed to DEX on E14.5, generated 39% more progeny compared 
to controls as seen by the number of BrdU+ cells in the cortical wall on E17.5. Number of BrdU-positive 
cells ± SD, Student’s t-test, n = 6; Control 208 ± 23, DEX 290 ± 28, p < 0.001. 
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Figure 25. S-phase NSPCs exposed to DEX on E14.5 undergo precocious neurogenesis and generate a higher 
proportion of neuronal progeny that populate the plate on E17.5. A, B. A higher proportion of BrdU-
labelled progeny of E14.5 NSPCs populate the cortical plate on E17.5. Contrary, a smaller proportion of 
BrdU+ cells are found in the progenitor zone (PZ) of the DEX–treated embryos. % BrdU-positive cells 
per zone over total BrdU ± SD, Student’s t-test, n = 6; CP: Control 208 ± 23, DEX 290 ± 28, p < 0.001. 
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3.3.5 A single DEX exposure on E14.5 increases the number of NSPCs progressing 
through S-phase. 
Midgestation is a time of critical changes in the neurogenetic process, whereby the cortical plate 
increases in size as a result of the neurons generated from RGCs and IPCs. At this age, 
neurogenesis reaches its maximal (Sun and Hevner, 2014). Therefore, we expected that DEX-
induced GR signaling on E14.5 would affect neurogenesis. Since we already observed an 
increase in the NSPCs that had gone through the S-phase (BrdU+) 72 hours after DEX exposure, 
we examined whether this change would be evident after 24 hours, which is a few hours longer 
than the average duration of the cell cycle on E14.5 (Takahashi et al., 1994; Takahashi et al., 
1995; Takahashi et al., 1997; Takahashi et al., 1999). Thus, E14.5 DEX-treated embryos were 
given a pulse of BrdU and collected after 24 hours, for cell cycle analysis. In DEX-treated 
cortices, BrdU+ cells formed a thicker zone within the VZ compared to the controls (Figure 26). 
In addition, the position of the BrdU+ zone in the basal VZ and SVZ was thicker and 
approximately 1 cell diameter above the corresponding BrdU+ zone in the controls (Figure 26).  
Consistent with our findings at E17.5, we observed a 24% increase in the number of BrdU 
positive cells in DEX-treated embryos compared to the controls after 24 hours (Figure 26). This 
result was also verified by FACs analysis of dorsal cortices from E14.5 embryos exposed to 
DEX and BrdU for 24 hours (Figure 26). By using the FACs method the difference in the 
proportion of BrdU+ cells, rose to 56% (Figure 26).  Therefore, these results suggest that DEX-
induced GR signaling on E14.5, causes an increase in the proportion of NPSCs going through the 
S-phase which results in an increased production of neurons.  
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Figure 26. A single DEX exposure on E14.5 increases the number of NSPCs progressing through S-phase 
after 24 hours. A-C. The number of BrdU+ cells that progressed through the S-phase, is increased by 24% 
in DEX-treated cortices. Number of BrdU+ cells ± SD, Student’s t-test, ncontrol = 4, nDEX = 6; Control: 156 
± 12, DEX 194 ± 16, p <0.01. D. FACs analysis of dorsal cortex samples exposed to DEX for 24 hours 
verified the increase in BrdU: Proportion of BrdU+ cells, Control n=6, 29 ± 10, DEX n=7 49 ± 6, p < 
0.01. 
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3.3.6 DEX induces an increase in the number of IPCS  
At mid-gestation the IPC population increases in size (Attardo et al., 2008). Due to the critical 
contribution of IPCs at this stage and onwards to neuronal production we examined whether this 
progenitor population was affected by DEX by performing immunofluorescence staining for 
Tbr2, a specific marker for IPCs. Interestingly, an increase in IPCs was evident in the DEX-
treated cortices. Moreover the Tbr2+ cells occupied a wider area due to a wider Tbr2+ VZ zone 
and a wider bVZ/SVZ zone, which was approximately 1 cell diameter higher and wider 
compared to the controls (Figure 27). Analysis of the IPC numbers revealed that DEX had 
promoted a 28% increase in these embryos compared to the controls (Figure 27).  
 
 
 
Figure 27. Exposure of E14.5 NSPCs to DEX results in an increase in the number of IPCs after 24 hours. A, 
B. The number of Tbr2+ cells is increased by 28% in DEX-treated cortices. C. Number of Tbr2+ cells ± 
SD, Student’s t-test, ncontrol = 4, nDEX= 6; Control: 186 ± 27, DEX 238 ± 5.5, p <0.01.  
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Figure 28. Indirect RGC neurogenic division to IPCs. RGCs can give rise to IPCs by indirect neurogenic 
divisions by dividing to one RGC and one IPC. If the IPC committed-RGC was passing through S-phase 
then it would accumulate BrdU+ and give rise to Tbr2+/BrdU+ cells. 
3.3.7 Cell cycle phase-dependent effect of DEX on RGC fate. 
RGCs divide symmetrically to give rise to two RGCs (self-renewing divisions) or 
asymmetrically to generate one IPC and one RGC or a neuron and one RGC (Pontious et al., 
2008) and Figure 28. Therefore, we wondered whether the increase in BrdU+ cells and Tbr2+ 
cells following 24 hours of DEX exposure, was a result IPCs generation from NSPCs that went 
through the S-phase (Englund et al., 2005). Quantification of the number of Tbr2+/BrdU+ cells 
versus Tb2+/BrdU-, revealed that the increase in the IPC population in the presence of DEX, was 
actually due to an increase in Tbr2+/BrdU- cells (Figure 29B). Thus, this result suggested that 
the increased number of IPCs in the DEX-treated cortices were derived from RGCs that had not 
passed through the S-phase while DEX was acting. 
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Figure 29. DEX induces IPC fate in RGCs that were not in the S-phase. The number of Tbr2+/BrdU- cells 
was increased by 32% in the cortices of E14.5 embryos that were exposed to DEX for 24 hours.  Number 
of Tbr2+/BrdU- cells ± SD, Student’s t-test, ncontrol = 4, nDEX= 6; Control: 116 ± 19, DEX 158 ± 7.3, p < 
0.01. 
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Figure 30. Direct RGC neurogenic divisions. Proliferative RGCs can switch to a neurogenic mode, and re-
enter the cell cycle in the progenitor zone (PZ) as neurogenic RGCs which then can divide and give rise 
to neurons that migrate to the intermediate zone (IZ). If the proliferative RGCs were in S-phase during 
this transition and exposed to BrdU, then progeny will also contain the BrdU label. 
 
Furthermore, the above result raised the question of what was the fate of NSPCs that went 
through the S-phase during DEX exposure. Since the majority of progenitor cells in the VZ on 
E14.5 are RGCs (Arai et al., 2011), counting the number of Tbr2-/BrdU+ cells in the VZ is an 
indirect way to evaluate S-phase RGCs that have re-entered the cell cycle and remained in the 
VZ (Re-S-RGCs) (Figure 30). Following this approach we observed a 32% increase in the 
number of re-entering S-RGCs (Figure 31). Furthermore, we observed a 31% increase in the 
number of Tbr2-/BrdU+ cells outside of the PZ, which reflect the neurons directly produced by 
NSPCs in S-phase (Figure 31). Specifically a proportion of these neurons may reflect a 
contribution from the S-phase RGCs that re-entered the cell-cycle after DEX exposure, and 
divided giving rise to one neuron and one RGC, since the Tbr2-/BrdU+ cells in the VZ reflect a 
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mixed population of cycling neurogenic RGCs and their neuronal progeny. In neurogenic IPCs 
the expression of neuronal markers is present by M-phase, and Tbr2 expression persists at the 
initial stages of the postmitotic neuron (Englund et al., 2005). Therefore DEX may have also 
promoted the terminal divisions of neurogenic S-phase IPCs and lead to downregulation of the 
Tbr2 expression in the postmitotic neurons, which would also add to the increased number of 
Tbr2-/BrdU+ cells we observed in the IZ.   
 
Overall these results, suggest that DEX promotes neurogenesis by differentially affecting 
progenitors depending on the phase of the cell cycle. Specifically, in non-S-phase RGCs, DEX 
promoted the IPC fate (indirect neurogenic effect). In S-phase progenitors, it promoted 
neurogenesis and specifically by stimulating cell cycle re-entry of S-phase RGCs and promoting 
acquisition of neurogenic fate (direct neurogenesis). Also, it is likely that in S-phase IPCs DEX 
promoted their neurogenic divisions and accelerated downregulation of Tbr2 in the postmitotic 
neurons. Overall, these changes were reflected as an increase in the neurons in the IZ (Tbr2-
/BrdU+). 
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Figure 31. DEX exposure on E14.5 induces precocious neurogenesis in S-phase NSPCs.  A. In DEX-treated 
embryos the number of neurons (Tbr2-/BrdU+) in the IZ is increased by 31%, while the number of S-
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phase RGCs that re-entered the cell cycle and are in the progenitor zone (PZ), is increased by 32%, B, 
suggesting that S-phase RGCs (Tbr2-/BrdU+) re-entered the cell cycle as neurogenic progenitors which 
gave rise to neurons in the 24 hour window. Also, DEX may have promoted and accelerated (dashed 
arrow) neurogenesis by S-phase IPCs which would also contribute to the increased number of Tbr2-
/BrdU+ neurons in the IZ. Number of Tbr2+/BrdU- cells in each zone ± SD, Student’s t-test, ncontrol = 4, 
nDEX= 6; Tbr2-/BrdU+ Total:  Control 86 ± 5.3, DEX 113 ± 17, p < 0.01; Tbr2-/BrdU+ PZ:  Control 58 ± 
5.8, DEX 77 ± 13, p < 0.05; Tbr2-/BrdU+ IZ:  Control 28 ± 3.5, DEX 36 ± 7.2, p < 0.05. 
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 Figure 32. Model for differential effects of DEX on RGC fate depending on the cell cycle fate.  A. In E14.5 
non-S phase RGCs, a 24 hour DEX exposure promotes the IPC fate, reflected as an increase in the 
number of Tbr2+ cells. B In S-phase RGCs DEX promote cell cycle re-entry and direct neurogenesis, 
reflected in increased number of Tbr2-/BrdU+ cells in the progenitor zone and intermediate zone 
respectively. 
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3.3.8 FACS analysis and gene expression data support that DEX-induced GR signaling on 
E14.5 leads to cell cycle-phase dependent effects on RGC fate. 
The regulation of cell cycle exit in progenitors is a critical factor for the construction of the 
cortex. Increase in the progenitor re-entry in mutant embryos with a constitutively active form 
(Chenn and Walsh, 2002; Chenn, 2008). Moreover, in cortices of midgestation embryos in which 
the endogenous levels of Axin (effector of β-catenin) were artificially increased, the number of 
IPCs increased due to augmented contribution from RGCs. This led to an increase in cortical 
thickness on E17.5 (Fang et al., 2013). Contrary, we show that E17.5 embryos exposed to DEX 
on E14.5, have a reduction both in cortical surface and cortical thickness. Therefore, these results 
taken together suggest that DEX-induced GR signaling on E14.5 has a distinct effect on 
proliferating RGCs, depending on whether the cells were in S-phase (BrdU+) or not (BrdU-) and 
overall promotes precocious neurogenesis. We hypothesized that this could occur if DEX 
promoted an IPC fate in non-S-RGCs (Tbr2+/BrdU-, Figure 32A) or alternatively, in S-RGCs, 
DEX may promote re-entry as neurogenic progenitors and subsequently leading to the generation 
of neurons (Tbr2-/BrdU+). The average length of the S phase and G2+M phase of RGCs at 
E14.5 is approximately 5 and 2.5 hours, respectively, while the cell cycle lasts around 19.5 hours 
(Arai et al., 2011) and Figure 32.  Therefore, after 24 hours, BrdU+ labelled cells that re-entered 
the cell cycle, will either be in the G2M phase, have exited the cell cycle as neurons in G0 phase, 
or re-entered the cell cycle and are in G1 phase (Figure 33A). Therefore we decided to evaluate 
whether the distribution of BrdU+ cells within the cell cycle supported this hypothesis. For this 
purpose, we collected dorsal cortices from E14.5 embryos that were exposed to DEX and BrdU 
for 24 hours and processed them for FACS analysis. Indeed, DEX treatment resulted in an 
increase in the proportion of BrdU+ cells that were in the G0G1 phase, with a parallel reduction 
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in the proportion of BrdU-G0G1 cells (Figure 33B), reflecting an increase in BrdU+ RGCs that 
had re-entered the cell cycle (G1 phase) and committed to become neurons (G0). Also, the 
increased in G0G1 BrdU+, may also reflect a contribution from neurogenic S-phase IPCs that are 
either in G1 or have generated neurons (G0). Moreover, in DEX treated embryos there was a 
trend for increased proportion of BrdU+ cells in the G2M phase reflecting the neurogenic 
progenitors that re-entered the cell cycle (Figure 33B). Thus, we hypothesized that following 
DEX-induced premature GR signaling induces S-phase progenitors to adopt a neurogenic 
behavior, which was reflected with an accumulation of BrdU+ cells in G0G1 phase. 
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Figure 33. FACs analysis reveals a neurogenic shift in S-phase BrdU+ progenitors, after 24 hours of DEX 
exposure. A. S-phase RGCs exposed to DEX re-enter the cell cycle as neurogenic BrdU+-RGCs, and after 
(B), 24 hours accumulate in G1G0 reflecting an accumulation of BrdU+ neurons in G0. Proportion of 
(BrdU± G0G1) ± SD, Student’s t-test, ncontrol = 6, nDEX= 7 (biological replicates); BrdU+G0G1 Control 24 
± 9.2, DEX 37 ± 9, p < 0.05; BrdU- G0G1:  Control 64 ± 9.7, DEX 47 ± 7.1, p < 0.01. 
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3.3.9 DEX-induced premature GR signaling in RGCs promotes downregulation in c-Myc 
The proliferation of neural progenitors is tightly controlled by many signaling cascades. We have 
shown that in cultured neural stem cells, DEX-induced GR signaling by membrane GRs in 
association with caveolin 1 (Cav1) and through a Src/PI3K cascade  promote cell cycle exit and 
reduced proliferation (Peffer et al., 2014; Samarasinghe et al., 2011). Moreover, in another cell 
system, it was shown that membrane GR in association with Cav1 promotes activation of 
GSk3β, which is part of the Wnt pathway. The latter, is crucial for the regulation of neurogenesis 
and maintenance of the proliferation. Interestingly, the inhibition of cellular proliferation by 
DEX is mediated by an increase in GSK3β activity. The increased activity of GSK3β is reflected 
by reduced levels of downstream targets such as cyclin D1, c-Myc (Boku et al., 2008; Gulino et 
al., 2009; Heine and Rowitch, 2009; Nuutinen et al., 2009). Also, deletion of Gsk3β in neural 
stem cells, leads to aberrantly increased proliferation of RGCs with concomitant reduction in IPC 
production in vivo and upregulation of the proto-oncogene c-Myc (Kim et al., 2009; Kim and 
Snider, 2011) which is critical for neural stem cell self-renewal and differentiation and its 
functions are developmental stage specific. Specifically, in vivo conditional inactivation of c-
Myc in neural stem cells on E15.5, leads to neuronal differentiation of the affected cells, whereas 
when inactivation occurs on E17.5, these cells produce glia (Nagao et al., 2008). The n-Myc 
gene, which belongs in the same family of transcription factors as c-Myc, was shown to be 
functionally complementary of c-Myc in regulating proliferation (Malynn et al., 2000). 
Interestingly, conditional inactivation of n-Myc in neural progenitors, causes precocious 
neurogenesis (Knoepfler et al., 2002). C-myc has also been known for years to be downregulated 
by DEX (Reed et al., 1985; Thulasi et al., 1993; Wood et al., 1994). Cav1 is highly expressed in 
the apical side of the neuroepithelium and colocalizes with GR in RGCs that express the receptor 
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in their cytoplasm both on E11.5 and E13.5 (Figures 34A, B). To evaluate the levels of c-Myc 
expression in the presence of DEX, we exposed E11.5 embryos to DEX for 8 hours and then the 
dorsal cortices were collected for analysis of c-Myc mRNA expression by qRT-PCR. At E11.5, 
RGCs make up 90+% of the proliferative population, whereas the numbers of neurons and IPCs 
are very low (Englund et al., 2005) and Figure 21. Thus, by approximation at this age we would 
mainly evaluate the levels of c-Myc in RGCs. Moreover, the cell cycle duration on E11.5 is ~8 
hours (Takahashi et al., 1995), allowing us to evaluate c-Myc mRNA changes within the scope 
of an entire cell cycle. These results showed that DEX-induced GR signaling on E11.5 indeed 
reduces the levels of c-Myc mRNA (Figure 34C). Therefore considering the role of c-Myc in 
Gsk3β/Cav1/GR signaling and neurogenesis, it is tempting to assume that part of the mechanism 
by which DEX-induced premature GR signaling promotes precautious neurogenesis runs through 
downregulation of c-Myc by activation of a Cav1/Gsk3β dependent signaling cascade. 
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Figure 34. Premature activation of GR signaling by DEX in E11.5 NSPCs of the dorsal cortex induces 
downregulation of c-Myc after 8 hours. A, B.  Cav1 colocalizes with GR in NSPCs of the aVZ of the E11.5 
and E14.5 cortex (yellow arrows). In both ages Cav1 expressed in relatively higher levels in the 
hippocampus (white arrowheads). C. The expression of c-Myc, a putative target in GR-Cav1 signaling, is 
downregulated in E11.5 dorsal cortices exposed to DEX for 8 hours.  Fold expression levels (2 (-ΔΔCt)), 
n=3 biological replicates (Dorsal Cortex): Control 1 ± 0.22, DEX 0.57 ± 13, p < 0.05. 
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3.4 DISCUSSION 
We have previously shown that GR is expressed both in cortical RGCs and IPCs on E14.5 and 
that it is nuclear in the majority of the progenitors with the exception of apical RGCs that have a 
distinct cytoplasmic GR profile (Tsiarli et al., 2013); See Section 2.3.4). The nuclear profile of 
GR suggested that the receptor may have a functional role in neuronogenesis that is regulated by 
GC-independent mechanisms, since before E16 the brain is essentially GC-naïve (Venihaki et 
al., 2000). Moreover, it has become clear that GR is functional in the absence of GCs and serves 
as a homeostatic regulator of gene expression. Furthermore, addition of GCs disrupts this 
homeostatic balance and shifts the scale to GC-induced GR signaling (Ritter et al., 2012; Ritter 
and Mueller, 2014). In this study we show that premature activation of GR signaling by a single 
DEX course on E14.5, disturbs the normal process of development by favoring neuronogenesis 
at the expense of proliferation in RGCs. This has as a consequence, the supernumerary 
production in neurons of all layers, reduction in the cortical surface and thickness which is 
manifested overall as impaired brain growth on E17.5, 72 hours after the DEX injection. 
Moreover, DEX leads to permanent effects on the cortical cytoarchitecture and cognitive 
function of the adult animal. 
3.4.1 Cell cycle phase-dependent effects of the prematurely DEX-activated GR on RGC fate. 
It has been suggested that GR subcellular localization is intimately connected to its function in 
proliferating cells and furthermore it is linked to the cell cycle phase (Hsu et al., 1992; Hsu and 
DeFranco, 1995; Matthews et al., 2011). In GC-naïve conditions, the receptor accumulates in the 
cell nucleus from late G1 until the G2 phase, a slow process lasting for hours. During the M 
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phase, the receptor is rapidly excluded from the dividing chromosomes, whereas during early 
G1, GR is rapidly excluded from the nucleus (Matthews et al., 2011). GR function is modulated 
by baseline post-translational modifications in the form of phosphorylation that also differ 
depending on the kinases and phosphatases that are active during a specific cell cycle phase 
(Ismaili et al., 2005; Oakley and Cidlowski, 2013). Specifically, phosphorylation on Serine 211 
(S211) during G1, can prime the receptor for increased responsiveness to GC-mediated signaling 
(Matthews et al., 2011). RGCs are the major proliferative cell type in the cortex (Pontious et al., 
2008; Sun and Hevner, 2014) and contribute to neuronogenesis either directly or indirectly 
through the generation of IPCs. As we have previously shown, RGCs have a distinct GR 
expression profile (Tsiarli et al., 2013) which is in accordance to the cell cycle phase-related 
localization of GR as has been described by Mathews et al., (2011), whereby mitotic RGCs in 
the apical VZ mainly express cytoplasmic GR, whereas basal RGCs express nuclear GR. The 
results presented in this study also suggest that premature DEX-induced GR signaling, leads to 
differential effects on RGC fate depending on whether the cell was in S-phase or not during the 
critical window of DEX action. Specifically, after 24 hours, DEX induced an increase in the 
number of NSPCs that had gone through the S-phase and were positive for BrdU (28% increase 
over control). The increase in BrdU+ cells was localized within the RGC population, since it was 
reflected with an increase in the numbers of BrdU+ RGCs (Tbr2-/BrdU+; 32% increase).  
Overall these results suggest that premature DEX-induced GR signaling, promotes neurogenesis 
from RGCs either directly by forcing re-entry of S-phase RGCs as neurogenic progenitors which 
then divide asymmetrically to one neuron and one RGC that re-enters the progenitor zone, or 
indirectly by promoting the generation of IPCs from non-S phase RGCs.  In other systems such 
as the hematopoietic system, activation of GR by DEX, promotes proliferation of erythroid 
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progenitors, cancer cells including neuroblastoma cells and osteoblasts (Gruver-Yates and 
Cidlowski, 2013; Gundisch et al., 2012; Langeveld et al., 1992; McCulloch and Tenenbaum, 
1986; Panzenböck et al., 1998). Interestingly, in the case of osteoblasts, the pro-proliferative 
effects of the activated GR are actually directed to a cycling cell population that is primed to 
differentiate (McCulloch and Tenenbaum, 1986), hence GR signaling promotes differentiation.  
DEX activation of GR promotes G1 arrest in cycling neural progenitors in vitro, by 
stimulating p53 nuclear translocation and transcription of p21, nonetheless, without promoting 
apoptosis (Crochemore et al., 2002). It is possible that one likely mechanism by which DEX-
induced GR signaling ultimately promotes neurogenesis in S-phase RGCs (Tbr2-/BrdU+), is by 
initiating a similar signaling cascade as the one reported by Crochemore et al., (2002). 
Specifically, DEX-induced GR signaling may indirectly, promote activation of the p53/p21-
dependent cell cycle control, via inhibition of BRCA1 expression. Is its known, that the 
unliganded GR, positively regulates the expression of BRCA1 by direct association with the 
BRCA1 promoter. Interestingly this association is repressed following 24 hour exposure to GCs 
(Ritter et al., 2012; Ritter and Mueller, 2014), thus providing a reasonable hypothesis on how 
DEX may be acting in NSPCs. BRCA1 is essential for cortical development (Pao et al., 2014; 
Pulvers and Huttner, 2009). Loss of BRCA1 results in nuclear translocation of p53 and apoptosis 
in vivo, whereas neural progenitors in culture with half dose of BRCA1 continue to proliferate 
(Pao et al., 2014).  The axis GR-BRCA1/p53-p21 is likely to be the mechanism by which DEX 
promotes neurogenic divisions in S-phase RGCs, since it goes along with the above observations 
that a G1 arrest by DEX primes neural progenitors for differentiation (Crochemore et al., 2002). 
Accordingly, in the 24 hour DEX-treated embryos a greater number of S-RGCs re-entering the 
cell cycle and at the same time a concomitant increase in neurons produced by S-phase 
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progenitors (Tbr2-/BrdU+), suggesting that S-phase RGCs where primed by DEX to re-enter the 
cell cycle as neurogenic progenitors. Moreover, due to the interkinetic nuclear migration that 
RGCs undergo, S-phase RGCs are located in the basal aspect of the VZ. BRCA1 is most highly 
expressed in the cortical neuroepithelium during the peak of proliferation (~E14.5). Additionally, 
its expression is higher in the basal parts of the progenitor zone (Pao et al., 2014) and thus, 
reminiscent of the high nuclear GR expression in the same zone (Tsiarli et al., 2013), see section 
2.3.3). Thus the spatial localization of GR and BRCA1 would be in agreement along with the 
existence of a GR-BRCA1/p53-p21 axis in these cells. Moreover, there has been a number of 
results associating different DEX-binding to GR according to the cell cycle phase and GR 
concentration itself.  Specifically, it was shown that during S-phase the proportion of DEX-GR 
in the nucleus is higher both in proliferating mouse and human lymphoid cells (Distelhorst et al., 
1984).  Moreover in HELA cells, the concentration of GR increases during entry in the S phase 
(Cidlowski and Cidlowski, 1982). The same phenomenon seems likely to apply in S-phase 
RGCs. S-phase RGCs are located in the basal VZ and have high levels of nuclear GR relative to 
their apical counterparts, putatively making them more vulnerable to DEX.  
Membrane-bound GR in association with caveolin 1 (Cav1), can also mediate rapid DEX 
effects on cell cycle regulation (Matthews et al., 2008a; Peffer et al., 2014; Samarasinghe et al., 
2011). Specifically, in the lung epithelial cell line A549, DEX promotes phosphorylation of 
Cav1, and protein kinase B (PKB)/Akt via the src kinase and leads to growth arrest and 
accumulation in G1/S (Matthews et al., 2008a). This pathway is also functional in neural stem 
cells in vitro and regulates their proliferation (Peffer et al., 2014; Samarasinghe et al., 2011).  
Moreover, in the A549 cells, Cav1-dependent rapid GR signaling, induced activation of 
glycogen synthase kinase-3β (Gsk-3β), and of the mammalian target of rapamycin (mTOR). 
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Interestingly, Cav1 levels are higher in the apical side of the VZ (Fig.3.16 A and B), coinciding 
with the zone of enhanced cytoplasmic GR expression on E13.5 (Tsiarli et al., 2013), Section 
2.3.3). RGCs on the apical VZ are either in mitosis, in late G2 or early G1, but not in S-phase. 
Therefore, in this sub-population of RGCs (non-S phase RGCs), activation of GR by DEX may 
promote GSk3β activation and subsequently, changes in Wnt signaling that promote production 
of IPCs cells from RGCs at the expense of their self-renewal (i.e., re-entry in the cell cycle as 
neurogenic progenitors that give rise to IPCs, and not as proliferative RGCs). GSK3β is a 
serine/threonine kinase, that is critical for the homeostasis of NPC function during cortical 
development (Kim and Snider, 2011). Specifically, GSK3β manages the exquisite balance 
between proliferation versus differentiation of NSPCs by being a principal regulatory component 
of the canonical Wnt/β-catenin pathway. The Wnt/β-catenin pathway is one of the major 
morphogenetic signals that promotes proliferation of NSPCs during development of the brain. 
The major effector of the pathway is β-catenin, which functions as a transcriptional inducer of 
cell cycle related genes such as Cyclin D1 and c-Myc (He et al., 1998). GSK3β phosphorylates 
not-activated β-catenin and tags it for degradation by the proteasome.  Interestingly, high GSK-
3β signaling has been proposed to promote asymmetric divisions of RGCs and the generation of 
IPCs and neurons (Hur and Zhou, 2010). Moreover, upregulation of axin, a regulator of the 
canonical Wnt pathway, which can also physically associate with GSK-3β (Kim et al., 2009; 
Kim and Snider, 2011) to promote β-catenin degradation, stimulates asymmetric divisions of 
RGCs to IPCs causing an increase in IPC number (Mao et al., 2009). Consistent with this 
reasoning, DEX promotes adipocyte differentiation in a GR-dependent manner, by upregulation 
of Axin 2 (Naito et al., 2013). Therefore, it is possible that in non-S-phase RGCs DEX promotes 
IPC production partially through rapid GR signaling and activation of GSK-3β signaling 
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cascades. Also, another putative player in the DEX-induced IPC generation from non-S-phase 
RGCs, might be mTOR, which was also shown to be a downstream target of rapid GR signaling 
(Matthews et al., 2008b). RGCs express Pax6, which is a critical regulator of neurogenesis. Pax6 
also regulates the transcriptional activation of Tbr2 and promotes the generation of IPCs 
(Englund et al., 2005; Fishell and Kriegstein, 2003; Kohwi and Doe, 2013). It has been shown 
that Tbr2 regulation by Pax6, occurs in a cell-autonomous manner and it is dependent on the 
activation of the mTOR complex 1 (mTORC1) pathway (Díaz-Alonso et al., 2014). Moreover, 
increased mTOR signaling promotes precocious differentiation of cortical progenitors at the 
expense of their proliferation (Magri et al., 2011).  
Another possible mechanism by which DEX-induced GR signaling may promote 
neurogenic divisions of RGCs either to neurons or IPCs is by altering the kinetics of the cell 
cycle. It is well established that the length of the G1 phase cycle in neurogenic progenitors is 
increased compared to proliferating progenitors, with the highest G1 length being of neurogenic 
IPCs at 21.3 hours. Neurogenic RGCs on the other hand have a G1 that lasts 11.7 hours (Arai et 
al., 2011). Moreover, neurogenic progenitors have a shorter S-phase compared to proliferating 
progenitors. Baghdassarian et al. (1998) showed in phytohemagglutinin-stimulated human 
lymphocytes, DEX causes as a primary response a lengthening in G1 phase with a parallel 
reduction in S-phase. After 24 hours S-phase is increased in length. Part of the mechanism by 
which DEX modulates G1 and S length is by promoting an increase in p27 levels. It is tempting 
to hypothesize that a similar mechanism involving p27 may be also taking place in DEX-exposed 
RGCs, and inducing a fate change from proliferating to neurogenic progenitors. The role of p27 
in promoting cell cycle exit and increase in G1 is well studied (Caviness et al., 2009; Nguyen et 
al., 2006; Tarui et al., 2005) and it has been suggested that p27 interacts with the Notch pathway 
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to regulate the progressive increase in G1 length during the normal course of neurogenesis 
(Caviness et al., 2009). 
3.4.2 Increased number of neurons in a smaller cortex 
3.4.2.1 DEX favors a neurogenic fate in RGCs, but with a price 
This study has shown that a single course of DEX at a clinically relevant dose on E14.5, leads to 
an impairment in brain growth, which is manifested as reduced cortical surface and reduced 
cortical thickness on E17.5. Nevertheless, despite the reduction in cortical thickness, these 
animals have increased neuronal numbers corresponding to an increase in all cortical layers as 
seen with specific laminar markers. However, we cannot preclude that this increase is actually an 
increase in packing density rather than an increase in neuronal number per se, since precocious 
differentiation would eventually lead to a smaller overall cortex. Along these lines, a depletion of 
the progenitor pool in the form of asymmetric divisions, would also favor neuronogenesis at the 
expense of gliogenesis, which starts around E16 (Rowitch and Kriegstein, 2010). Preliminary 
results from this study, in embryos exposed to a single course of DEX on E14.5 and collected on 
P22, indicate that these animals show alterations in the white matter and specifically in the 
corpus callosum. Impairments in myelination as a result of antenatal GC exposure have been 
shown in multiple studies (Braun et al., 2013).   
Furthermore, changes in cortical thickness and surface, are directly linked to the RGC 
progenitor pool and their ability to shift from a mainly symmetric self-renewal state to 
asymmetric neurogenic divisions that give rise to IPCs or neurons. Accordingly, deletion of FGF 
genes (R1-3), that control this developmental fate shift, results primarily in an increase in RGC-
born IPC, with a concurrent depletion in RGCs which ultimately leads to a reduction in cortical 
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thickness and surface (Kang et al., 2009). Moreover, Pilaz et al. (2009) demonstrated that an 
induced reduction – rather than increase- in the length of G1 by overexpression of cyclin D1 or 
E1 on E15, leads to an initial increase in the self-proliferation of RGCs only to switch to 
increased production of IPCs after 24 hours. Our FACs analysis showed that DEX exposure for 
24 hours resulted in an decrease in the proportion of BrdU- cells that are in G1, whereas, the 
proportion of BrdU+ cells in G1 was increased (Section 3). This differential DEX effect 
depending on whether the cells had gone through the S-phase (BrdU+) or not (BrdU-), again 
suggests differential effects of DEX-induced GR signaling in RGCs depending on whether the 
cells were in S-phase.  
Since the increase in Tbr2+ IPC cells was driven by RGs that were not in S-phase during 
the DEX-induced GR signaling, it is tempting to assume that a similar signaling events such as 
the one described by Pilaz may be induced in non-S-phase RGCs. Moreover, Pilaz and 
colleagues (2009) showed that even if G1 is altered in progenitors, they continue to produce the 
right neuronal progeny for the respective developmental stage but, at the expense of the previous 
neuronal layer which was “skipped” due to the G1 increase. Specifically, the progenitors mainly 
produce LII/III on E15 and LIV production is reduced. Our results show that DEX induces an 
increase in neurons of all layers, further supporting a dual effect on RGCs, rather than promoting 
the generation of one layer at the expense of another. This result can be better explained if we 
hypothesize that the activated GR concomitantly induces the production of two neuronal waves: 
first it promotes asymmetric neurogenic divisions and the production of neurons primarily for 
deep layer V and at a less extent, deep layer VI, which are normally being born at E14.5 
(Takahashi et al., 1999). Concomitantly, GR promotes the production of upper layer II-IV 
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neurons either from S-phase RGCs or indirectly by the generation of IPCs from non-S phase 
RGCs (indirect neurogenesis).  
The distinct cytoarchitectural effects of DEX we observe on E17.5 are reminiscent of the 
cortical cytoarchitecture phenotype in reelin heterozygote mice, in which the thickness of the 
cortex is reduced albeit the neuronal packing density is increased. This is the end-result of a 
reduction in reelin-expressing cells in the adult brain, putatively of GAD67 interneurons which 
leads to a hypoplasia of the pyramidal neuron spines (Liu et al., 2001). Interestingly, postnatal 
(P) DEX exposure of P3 mice pups, increases the proportion of interneurons in the cortex with a 
parallel decrease in cortical thickness (Baud et al., 2005). Even though this study used postnatal 
mice, it indicates that DEX may have an effect on interneuron genesis and biology.  
Although we have not explored the effects of premature DEX-induced GR activation on 
interneuron genesis, we have shown that GR is highly expressed in interneuron progenitors 
(Sox2+) and mature interneurons of both of the medial and lateral ganglionic eminence (MGE 
and LGE), the former being a major source of cortical interneurons (Batista-Brito and Fishell, 
2009). GR expression in the apical progenitors of the GE, which also undergo INM (Pilaz et al., 
2009) is similar to the apical progenitors of the cortex where a strong cytoplasmic GR profile is 
observed (Tsiarli et al., 2013). Therefore, premature activation of GR signaling in interneuron 
progenitors may affect their proliferation, migration and integration in the cortex, including their 
reelin production and contribute to the changes we observed in cortical cytoarchitercture. 
Interestingly, Tbr2+ progenitors were shown to have a role in attracting and guiding subpallial 
interneurons to migrate and integrate in the cortex. Deletion of the Tbr2+ cells results in reduced 
numbers of interneurons in the cortex on E18.5 (Sessa et al., 2010). Thus another mechanism by 
which DEX indirectly may have affected the dynamics of interneurons is through the increase in 
 126 
Tbr2+ cells which could attract more cortical interneurons and thus contribute to the increased 
number of DAPI+ cells we observed in the cortical plate.  
Interestingly, increased glucocorticoid levels have been shown to have differential effects 
on brain reelin expression depending on the age and the sex of the animal. Specifically, exposure 
to repeated stress during the sensitive neonatal period, permanently increases the levels of 
hippocampal reelin expression in male mouse pups but not in females (Gross et al., 2012). 
Contrary, repeated exposure of adult rats to corticosterone over a span of 21 days but not to 
restraint stress, reduces the number of reelin immunoreactive cells in the hippocampus and 
promotes the development of depressive symptoms (Lussier et al., 2011). The hippocampus is 
densely populated with GRs, and as we have shown ((Tsiarli et al., 2013), Section 2) this applies 
from the very early stages of hippocampal morphogenesis, thus making it particularly vulnerable 
to the effects of GCs. The aforementioned studies, highlight the different effects of GR signaling 
on reelin signaling cascades, depending on the developmental stage.  
Beyond its traditional role in neuronal migration, reelin has a very important role in 
neurogenesis which only recently has started to draw attention. Specifically, reelin is secreted by 
the Cajal Retzius cells, a transient cell population that resides in the marginal zone during the 
embryonic life and is critical for instructing the migration of the nascent neurons to their 
respective position in the cortical plate (Gil-Sanz et al., 2013). The onset of neurogenesis 
coincides with the appearance of the Cajal Retzius cells and the initiation of reelin production. 
Also, the switch of symmetric to asymmetric neurogenic divisions in RGCs in the progenitor 
zone, is tightly under the control of the Notch pathway (Fishell and Kriegstein, 2003). Reelin 
induces activation of the Notch pathway in RGCs and promotes the shift in the asymmetric 
divisions of RGCS and thereby controlling neuronogenesis (Lakoma et al., 2011). Reelin gain-
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of-function in neural progenitors under the nestin-driver in vivo, induces upregulation of Notch 
target genes, NICD and Hes1, which is accompanied with increased IPC (Tbr2+) numbers, 
increased cell cycle exit and neuronogenesis. The effect of reelin in acting upstream and 
enhancing Notch signaling in RGCs and thereby regulating their fate, is independent on its 
function on postmitotic neuron migration (Lakoma et al., 2011). As we have showed, GR 
expression is highest in Cajal Retjius cells and specifically it is intensely nuclear (Tsiarli et al., 
2013, see section 2.3.2.2).  
Considering the connection of glucocorticoids with reelin expression in the postnatal 
brain, we can speculate that premature activation of GR signaling by DEX promotes 
upregulation of reelin, which in turn acts on RGCs and enhances Notch signaling to promote 
asymmetric divisions and precocious neurogenesis resulting then in increased neuronal numbers 
and a smaller cortical plate. Interestingly, corticosterone induces upregulation of reelin 
expression in osteoblasts (Ma et al., 2012). Moreover it is important to note that reelin has been 
in the spotlight in relation to the pathogenesis of neuropsychiatric disorders. Considering that 
increased GC levels during pregnancy have been also linked to the pathogenesis of 
neuropsychiatric and affective disorders, the role of GR in affecting reeling signaling during 
development, is definitely an association needed to be explored in depth. 
3.4.3 Relation to previous studies on prenatal GC effects on the developing brain.  
GCs effects on the developing brain have been the topic of many studies, especially following 
their introduction in obstetrics for the management of preterm labor. In agreement with the 
results from most studies, we show that a single injection of a clinically relevant dose of DEX 
leads to a reduction in brain growth in terms of reduced brain to body weight ratio and also 
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reduced cortical surface and thickness. Interestingly, in our model, body weight was slightly and 
significantly increased, but still this increase in body weight was not followed by a comparable 
trend in brain weight (Section 3). This apparently discordant effect of DEX on body weight can 
be explained by the fact that many of the studies that have shown a reduction in birth weight 
used either higher doses of DEX and/or used multiple courses of DEX and at different 
gestational stages (Noorlander et al., 2006; Noorlander et al., 2008; Noorlander et al., 2014; 
Zuloaga et al., 2011), whereas we explored the effects of a single course of DEX at midgestation.  
In our case, a single course of DEX in a clinically relevant dose allows us to dissect the 
“baseline” effects of premature DEX-induced GR signaling, without the confounding effects of 
multiple injections or of higher and non-clinically relevant DEX doses. Along similar lines, our 
preliminary results of caspase-3 staining, did not reveal gross differences in apoptosis in the 
E17.5 cortex, following DEX exposure on E14.5. Contrary many studies have shown that 
prenatal DEX exposure leads to apoptosis (Sundberg et al., 2006; Zuloaga et al., 2011) which in 
turn may result in a smaller brain postnatally, with especially high impact on the hippocampus 
(Khozhai and Otellin, 2008; Uno et al., 1990; Uno et al., 1994). Again these studies have used 
multiple injections of DEX and/ or non-clinically relevant doses which would be toxic for the 
progenitors 
One unique feature of our experimental design is that the embryos are exposed to DEX 
before the endogenous GC-production begins i.e., before E16. Similarly in the human condition, 
DEX is administered between 24 -34 weeks of gestation for the management of preterm labor 
(WHO). During this age the brain undergoes a dramatic development shift which is mostly 
evident in terms of cortical surface expansion and concomitant elaboration of the cortical 
gyrification pattern (Kapellou et al., 2006). Additionally, while for the majority of gestation the 
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circulating GC levels in the embryo were low, due to the protective role of the placenta, they 
steadily increase close to term promoting organ maturation and priming the fetus for labor 
(Braun et al., 2013; Ishimoto and Jaffe, 2011). Therefore two important points need to be noted 
about this condition; first during the 24-34 week time-window that DEX is likely to be used, 
endogenous levels of GCs are low and secondly, this is a very sensitive period for brain 
development with highly dynamic changes in cortical development taking place. Our 
experimental design allows us to mimic the low-GC human embryonic brain environment while 
also, being as close as possible in terms of neurodevelopmental events.  
A series of studies from Noorlander and colleagues (2008, 2014) used the same DEX 
dose in mice, but instead chose E15.5 as the exposure time and examined the effects on 
hippocampal development at different pre- and post-natal stages. Interestingly, DEX lead to an 
increase in activated caspase 3 positive cells in the hippocampus and reduction of proliferation in 
terms of Ki67+ cell numbers. Moreover, DEX caused long-lasting effects on cortical function 
manifested in terms of impaired spatial learning and memory (Noorlander et al., 2008). At this 
point we have to note that in our study we used pure DEX (MW 392.4 g), rather than the 
clinically used DEX phosphate (MW 516.4 g) which contains sulfites as preservatives and was 
used by Noorlander and colleagues (2008, 2014). The advantage of using pure DEX over the 
phosphate form, is that it allows us to observe direct effects of prematurely induced GR 
signaling, without the intermediate steps that would intervene until the phosphorylated form 
hydrolyzes to bioactive DEX (Miyabo et al., 1981). Also, it has been suggested that the sulfites 
contained in the clinical DEX form may be actually causing neurotoxic effects in the developing 
brain (Baud et al., 2001). 
 130 
In addition our study was centered on the specific effects of premature DEX-induced GR 
activation on NSPC biology during the peak of neuronogenesis (E14.5, midgestation). 
Specifically we focused on the two major types of cortical progenitors the RGCs and IPCs, 
which in our knowledge is the first attempt to dissect the role of GR and its premature GC-
induced signaling on neurogenesis and distinct types of NSPCs in vivo. Also, we show that a 
single course of DEX results in an increase of cells going through S-phase as reflected with an 
increase in BrdU+ cells after 24 and after 72 hours, rather than reducing them as previous studies 
have shown (Sundberg et al., 2006). Interestingly, prenatal betamethasone (the second most 
common sGC used for the management of preterm labor) administered in rat embryos and at a 
clinical relevant dose, can lead to an increase in proliferation postnatally as seen by increased 
[3H]thymidine incorporation and without causing apoptosis (Scheepens et al., 2003).   
3.4.4 Homeostatic role for non-GC bound GR in neurogenesis? 
In many of the studies examining the effects of GCs on different organ systems and clinical 
settings, the role the GR beyond mediating the effects of GCs has largely been ignored. GR is a 
transcription factor and may be independently acting in the absence of its traditional GC ligands 
to modify target gene expression. Recently the role of unliganded GR in breast cancer has been 
explored. In wild type mammary cells, the unliganded GR positively and directly regulates 
BRCA1 expression by direct association on the BRCA1 promoter and in collaboration with 
GABP-β (Ritter et al., 2012; Ritter and Mueller, 2014). This positive regulation is disrupted 
when hydrocortisone is present, thus providing a foundation for the role of stress in BRCA1 
down-regulation seen in sporadic breast cancer (Ritter and Mueller, 2014). Furthermore, the 
same group recently showed that the role of unliganded GR in controlling gene expression 
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expands beyond BRCA1, to many other genes including genes that are critical in organogenesis 
such as Cyclin D2 (Ritter and Mueller, 2014). Importantly, cyclin D2 is implicated in the 
generation of IPCs and it is also expressed in the human SVZ (Glickstein et al., 2009). 
Interestingly, these studies have sparked another line of research focusing on GR as diagnostic 
factor in breast cancer. Vilasco et al. (2013), showed that BRCA1 levels are intimately linked 
with the levels of GR and its basal phosphorylation on S211 which is critical for “maximal 
activation of GC signaling (Chen et al., 2008; Matthews et al., 2011). Silencing BRCA1 
expression by siRNA, reduced both basal and DEX- induced levels of GR-S211. Within the 
context of the developing brain, we have shown that GR is highly expressed in the developing 
telencephalon and cortical neuroepithelium and it is mainly nuclear. Furthermore GR is 
expressed in a gradient along the rostro-caudal axis with higher expression levels in the caudal 
telencephalon and specifically in the hippocampus (Tsiarli et al., 2013). Moreover, DEX-induced 
GR-signaling can affect gene expression from an early age i.e., c-Myc on E11.5 (see Figure 
34C), making the hypothesis for a homeostatic role for the unliganded GR in neurogenesis very 
likely.  
The role of prenatal stress on the offspring is a topic that has been in the center of 
attention for many years now. Increased levels of GCs as a result of maternal stress can lead to 
permanent changes in the physiology of the offspring that impact metabolic and cardiovascular 
aspects but also cognitive function through a premature activation of GR and reprogramming in 
the basal functioning state of the HPA axis (Harris and Seckl, 2011; Reynolds and Seckl, 2012; 
Speirs et al., 2004). Importantly, with the advent of the genomics, changes in gene expression 
resulting from an adverse uterine environment during pregnancy, including increased GC levels, 
have been characterized as risk factors associated with the development of neuropsychiatric and 
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affective disorders (Huang, 2011; Lupien et al., 2009). Many of these genes or their products are 
linked to GR signaling such as Reelin and GABA, FKBP5 (Binder, 2009; Lussier et al., 2011; 
McEwen, 2005).  
The prefrontal cortex and the hippocampus two regions that are highly linked with the 
development of neuropsychiatric and affective disorders are highly enriched in GRs and the 
causative link between abnormal GR function and a risk for developing neuropsychiatric and 
affective disorders, has been shown in many clinical and non-clinical studies (McEwen, 2005; 
McGowan et al., 2009; Welberg and Seckl, 2001). Interestingly, examination of cortical 
thickness by MRI in school aged children, that were prenatally exposed to GCs (mean 
gestational age 28 weeks) but born at term, showed that there is a bilateral thinning of the cortex. 
The area mostly affected was the anterior cingulate cortex which is densely populated with GRs. 
Furthermore, cortical thinning in these children was associated with the development of affective 
problems (Davis et al., 2013).  These results point to a necessity for a better examination of GRs 
role in the developing brain, by looking at it through the prism of signal transduction of a 
dynamic transcription factor, rather under the strict line of GR being a mediator of GC effects. 
Obtaining a more clear understanding of the role of GR in the developing brain and its putative 
homeostatic/regulator role in neurogenesis in association with BRAC1, reelin or other molecules 
will allow a better understanding of the effects of GCs on the developing brain. Also, it would 
improve current GC treatments or lead to the development of new treatments characterized by 
more health benefits and reduced side-effects on neural development.  
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4.0  GENERAL DISCUSSION 
The introduction of sGCs in medicine for the management of preterm labor, has had a dramatic 
effect on neonatal morbidity and mortality. Undoubtedly, many neonates have been saved due to 
the meticulous and inspiring work of Dr. Liggins which lead to the discovery of the benefits of 
GCs in improving survival of preterm babies and reducing neonatal mortality due to the various 
complications of preterm labor. Nevertheless, no medicine is a panacea itself and as it is often 
the case potential side-effects are set aside in the light of major benefits. In utero exposure to 
GCs and especially sGCs that are resistant to placental degradation, will globally affect the 
developing embryonic organ systems, amongst them the brain. As we have shown, GR, the 
mediator of the intracellular effects of GCs, is expressed in the mouse embryo brain from very 
early stages of neurogenesis and moreover, it can affect gene transcription and alter NSPC 
properties when it binds DEX (Figure 3.16). Two major facts corroborate the hypothesis that the 
unliganded GR may be acting independently of GCs during this period to regulate neurogenesis: 
First, GR is expressed in high levels in the nucleus of the majority of progenitors and neurons of 
the neuroepithelium, but at the same time in apical progenitors it has a restricted cytoplasmic 
localization seen throughout the apical surface of the telencephalon. Secondly, binding of GR to 
DEX before the natural onset of GC production by the embryo (E16), results in changes in the 
proliferation of RGs and leads to impairment of cortical growth perinatally (this study) and 
behavioral changes that last in adulthood (this study, (Noorlander et al., 2008; Noorlander et al., 
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2014)). We do not refer to DEX binding to GR as activation since the unliganded GR has been 
clearly shown to have an active role in gene expression and maintaining homeostasis in the cell 
(Ritter et al., 2012; Ritter and Mueller, 2014; Vilasco et al., 2013). These observations highlight 
the fact that the function of GR should be re-evaluated, but not in a GC-centralized scheme, but 
rather as a dynamic transcription factor which is at the nexus of critical developmental signaling 
cascades. Its function is dynamically regulated by the cell cycle phase and at the same time, the 
GR itself regulates cell cycle (Ritter et al., 2012; Ritter and Mueller, 2014; Vilasco et al., 2013) 
ultimately affecting organogenesis and development. In many studies on the effects of increased 
GC levels in utero either as a result of stress, traumatic experience, and disease or due to 
exogenous treatment, the hippocampus and the prefrontal cortex have played the leading roles 
due to their tight association with the pathophysiology of neuropsychiatric and affective 
disorders and due to their high density of GRs. The expression levels of the GR dictate the 
amplitude of the GC response. Furthermore another aspect that is not frequently discussed, is that 
following a GC-induced GR signaling, the levels of the receptor are downregulated due to 
negative feedback. This mechanism has been associated with the pathogenesis of depression 
(Harris and Seckl, 2011; Ridder et al., 2005; Webster et al., 2002) and has been shown in victims 
of suicide with a background of childhood abuse (McGowan et al., 2009). Furthermore, exposure 
to DEX during the first week of life in mice, results in a permanent and specific downregulation 
of GR (Felszeghy et al., 1996), suggesting that side-effects of premature GC-GR binding in utero 
may not only be a result of altered signaling but also due to a permanent downregulation of the 
receptor in the affected areas. This hypothesis would especially affect those developing brain 
areas that are more susceptible to GCs due to their high density of GRs, such as the cortical 
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progenitor domain and the hippocampus (this study), as has been shown for neurogenesis in the 
adult hippocampus (Fitzsimons et al., 2013).  
GC actions can vary depending on the cell and tissue type and the age. Also, mouse 
models with genetically modified GR expression may differ in phenotypes and behavior despite 
seemingly having the same effect on GR levels or signaling.  This is attributed to the pronounced 
diversity of GR transcripts and isoforms which is a result of alternative splicing and/or 
posttranslational modification of the receptor protein (Oakley and Cidlowski, 2013). In the 
human cortex, GR variants are expressed in a dynamic pattern during critical periods of 
neuroplasticity and development of the pyramidal and astroglial components, reflecting 
vulnerability of the developing cortex to excessive levels of GCs (Sinclair et al., 2011). In these 
study, high nuclear localization of the main GR variant (GRα), was observed in the pyramidal 
neurons of the maturing frontal cortex suggesting a role for these cells in the stress response and 
is reminiscent of the high nuclear GR levels we observed in LV. Moreover during the first 
trimester of life, a transcriptionally hyporesponsive GR is prevalent, in agreement with the 
existence of a stress hyporesponsive period during the neonatal life. Therefore, considering this 
high degree of heterogeneity in GR isoforms, one must be careful on how to interpret results of 
GC action in the system of interest. Therefore it is tempting to speculate that such variability in 
GR variants may exist in the developing cortex niche and in the different progenitor types, 
allowing differential regulation of neurogenesis in a cell-type dependent manner. 
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In the light of accumulating data for a dynamic role of the unliganded GR in gene expression and 
cellular homeostasis, in combination to the results on the effects of premature GR “activation” 
on neurogenesis and cortical development contributed by the current study, the role of the 
unliganded receptor in these processes should be further explored, through a non-GC-centralized 
scheme. Having this knowledge would allow the improvement of current treatments not only for 
preterm labor management but also other clinical settings such as cancer and depression. 
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
5.1.1 CONCLUSIONS 
This study was fuelled by the combined fact that antenatal use of GCs can lead to detrimental 
effects on neurogenesis, cortical development and the offspring behavior and yet, the exact role 
of the GR in neural progenitors and in neurogenesis was not explored beyond its traditional view 
as a mediator of GC signaling. Nevertheless, it has become clear that GR is a dynamic 
transcription factor which can regulate, highly important developmental genes such as BRCA1, 
in the absence of GCs. Importantly in order for GR to maintain this regulatory profile, GCs 
should be absent. Therefore it is clear, that GR is emerging through this studies as a homeostatic 
regulator and a bona fide transcription factor lying in the nexus of many signaling cascades and 
which does not require GCs to function. Rather GCs, shift the regulatory profile of the receptor 
and alter its dynamic range of action. The results from my study corroborate for a homeostatic 
role of the unliganded GR in neurogenesis and cortical development which is tightly linked to 
the cell cycle phase. The homeostatic role of GR is disrupted by DEX and leads to precocious 
neurogenesis by altering neuronal progenitor properties depending on whether the progenitor 
was in S-phase or not. The line of data that support this notion are: 
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1. GR protein is highly expressed in neural progenitors from early neurogenesis i.e., E11.5 
2. It is predominantly nuclear regardless of the fact that the embryonic brain is GC-naïve 
before E16. 
3. Premature DEX-induced activation of GR on E11.5 causes downregulation of c-Myc 
supporting that GR is functional and responsive to GCs and premature activation of its 
signaling may disrupt its homeostatic role in neurogenesis. 
4. GR protein is differentially expressed in RGCs with apical RGCs expressing 
predominantly cytoplasmic GR, whereas basal RGCs express predominantly high levels 
of nuclear GR. This distribution is in agreement with a high nuclear expression of GR in 
interphase cells and especially in S-phase cells representing basal RGCs, and cytoplasmic 
expression in M phase cells, representing RGCs on the apical surface of the VZ. This 
distribution is in agreement with a cell cycle-dependent distribution and function of GR 
in the absence of GCs (Matthews et al., 2011). 
5. Accordingly, premature DEX-induced activation of GR signaling on E14.5 (GC-naïve 
conditions), promotes precocious neurogenesis by differentially affecting progenitor fate 
according to the cell cycle phase. In non-S-phase RGCs, premature GR activation 
induced indirect neurogenesis by promoting the IPC fate (28% increase in IPC numbers), 
whereas in S-phase RGCs, DEX promoted a competence shift and cell-cycle re-entry as 
neurogenic progenitors (direct neurogenesis). This was reflected as a 32% increase in the 
number of S-phase RGCs in the VZ reflecting a mixed population of cycling neurogenic 
RGCs and their neuronal progeny and a 31% increase in the number of neurons in the IZ. 
Moreover, DEX may have promoted/accelerated neurogenesis from IPCs, which could 
also have contributed in the increase in neurons of the IZ. This supports the notion that 
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premature DEX-induced GR signaling, disrupts a homeostatic role of the unliganded GR 
primarily in RGCs, and leads to precocious neurogenesis, either directly through S-phase 
RGCs or indirectly through the generation of IPCs from non-S phase RGCs. 
6. Disturbance of the homeostatic role of GR by DEX in E14.5 progenitors, lead to 
precocious neurogenesis, by promoting a neurogenic fate in progenitors, increase in the 
total neuronal output that populated the cortex, but in a smaller cortex both in the radial 
and lateral dimension. These results are in agreement with a depletion of the progenitor 
pool, by favoring a neurogenic fate when GR signaling is prematurely activated by DEX. 
Two points that support this conclusion: Studies showing an expansion of the RGC pool 
show that the cortex also expands at the lateral dimension (Chenn and Walsh, 2002). 
Furthermore, if the IPC population itself is expanded in the presence of DEX, we would 
expect an increase in the radial extent of the cortex as shown in many studies (Kim et al., 
2009; Pontious et al., 2008; Sahara and O'Leary, 2009). In addition, S-phase progenitors 
(BrdU+), generated a higher proportion of neuronal output (BrdU+) that occupied the 
cortical plate on E17.5 but a smaller proportion of these cells remained as progenitors in 
the progenitor zone on E17.5 suggesting that the self-renewing pool of progenitors was 
depleted in the presence of DEX because they acquired a neurogenic fate. This was also 
reflected as an increase in neurons of all layers including deep layer VI. If re-entry of 
both RGCs and IPCs had increased we would expect an increase mostly in deep layers 
but also an expansion in the cortical plate size as seen by Mairet-Coello et al. (2012). 
Nevertheless, in our study, despite the increase in neuronal number, the cortical size was 
smaller both in the radial and lateral dimension, supporting the notion that premature GR 
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activation of GR by DEX, favored a neurogenic fate in the progenitors and lead to a 
depletion of the progenitor pool. 
 
Collectively, my data suggest that the unliganded GR, has a regulatory role in the proliferation of 
neural progenitors and especially of RGCs. GRs’ regulatory role in RGCs is primarily 
highlighted by its’ distinct expression profile in apical versus basal RGCs, which is in 
accordance with a cell cycle phase-specific localization of GR and with the INM behavior of 
RGCs. Furthermore, the homeostatic role of unliganded GR in RGCs, is further supported by the 
fact that, premature DEX-induced GR signaling has differential effects on RGC behavior 
depending on the cell cycle-phase of the cells. This in turn reflects a differential function and 
responsiveness of the unliganded GR to GCs depending on the cell cycle phase of the progenitor. 
In addition, the results from this study are in accordance to previous published data from 
different cell lines (McCulloch and Tenenbaum, 1986), DEX-induced GR activation primed the 
progenitors to a neurogenic fate i.e., differentiation.  
 
Therefore my results support the view of the unliganded GR as a dynamic transcription factor 
which regulates cellular proliferation, neurogenesis and development and thus highlighting the 
need to decouple the view that GR functions solely through GCs. Rather, it should be considered 
that GR competence to activate and regulate cellular and developmental processes is intertwined 
with the demands of the cellular machine in response to intrinsic and extrinsic factors. GC 
activation is a switch to shift the competence of the GR towards maintaining the homeostasis of 
the cell in response to the changing environment. Adopting this view would allow a better 
understanding on the actions of GCs in different health and disease contexts. Also it can benefit 
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the improvement of current treatments not only for preterm labor management and avoid 
potential neurological side-effects in the neonates, which was the rationale behind this study, but 
also improve the use of GCs in other clinical settings such as cancer and depression. 
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5.1.2 FUTURE DIRECTIONS 
5.1.2.1 The effects of premature GR activation by DEX on E14.5 are permanent and are 
manifested as changes in cortical cytoarchitecture and in cognitive and affective behavior in 
the postnatal animal. 
One of the main questions one may have from the above results, is whether the effects of 
premature DEX-induced GR activation on neurogenesis leads to permanent changes in the 
offspring. To evaluate this possibility we conducted pilot studies that examine the cortical 
cytoarchitecture and behavior of animals that were exposed to DEX on E14.5 and used for 
analyses at different ages.  Pilot anatomical data derived from adolescent animals (Postnatal day, 
P22 group) exposed to DEX on E14.5, indicate that the depth of the corpus callosum is increased 
perhaps as a consequence of the increased number of neurons in the cortex that might contribute 
in white matter density. Alternatively, a change in the competency of the NSPCs at E14.5 5 
might have affected the progenitor pool that would later give rise to glia.7.  
  Interestingly, the formation of the corpus callosum is under the tight control of Satb2 and 
Ctip2 (Srinivasan et al., 2012). Cells of both types are increased following DEX exposure (See 
section 3.3.3, Figure 23B) and also, GR is specifically and highly expressed in layer V Ctip2+ 
neurons (See Section 2.3.2.6, Figure 15 ), suggesting that actions of DEX-induced GR signaling 
may not be limited in the progenitor stage but also extent to the postmitotic neuron. We aim in 
expanding these preliminary results by examining for other parameters that may have been 
affected in the postnatal cortex by prenatal DEX exposure, such as the presence of cortical 
                                                 
7 My personal contribution to this experiment was in designing the experimental setup, treating the animals 
and collecting and processing the brain tissue, whereas sectioning and pilot staining was performed by other 
colleagues. 
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interneurons and whether the morphology of the corpus callosum is altered due to the increased 
number of neurons, a change in gliogenesis or is a secondary effect from changes in fiber tracts.  
Furthermore, pilot behavioral data from DEX-treated animals (adult group) suggest that 
DEX may induce long-lasting behavioral abnormalities in adulthood8.  Adult animals (age 6-9 
months) were trained in different tasks such as the elevated plus maze and the open field test to 
examine anxiety. Preliminary data indicate that the DEX exposed animals show decreased 
anxiety such as by spending more time in the center and the open arms of the elevated plus maze 
and in the center of the open field. Therefore, these results show that even a single course of 
DEX at a clinically relevant dose given during midgestation, premature initiates GR signaling 
and leads to permanent changes in the cortical cytoarchitecture and the behavior of the animal. 
We plan to expand these results by evaluating the animals for additional behavioral tasks that 
may reveal more differences that are more subtle and more specific for certain regions. For 
example, fear conditioning can be examined with the use of the step-down avoidance task and 
depression-related behavior can be examined with the tail suspension test. 
5.1.2.2 Gene regulation by the unliganded and DEX-activated GR in neural progenitors 
It would be interesting to see how GR regulates gene expression and homeostasis in RGCs and 
IPCs, in basal unliganded conditions and following DEX treatment on E14.5. To approach this 
we could use FACs analysis to specifically isolate RGCs and IPCs, in combination with RNA-
seq analysis in samples of dorsal cortices that were derived from animals that were exposed to 
DEX or not (basal conditions). This would allow us to evaluate the transcriptional role of the 
unliganded GR in each of the progenitor population and compare how DEX affects it. 
                                                 
8  My personal contribution to this experiment, was to perform the treatment of the animals, whereas the 
behavioral testing and data analysis was performed by other colleagues. 
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Furthermore this analysis can be conducted in yet another level of detail, by specifically 
dissecting the role of the unliganded GR in RGC and IPC progenitors that are in different phases 
of the cell cycle. These experiments are very important since they can reveal new gene targets of 
GR in neural progenitors that control their proliferation and differentiation. Furthermore, this 
analysis would allow us to build a more specific model on how GR differentially regulates the 
proliferation and differentiation of RGCs versus IPCs and reinforce our conclusions for a role of 
the unliganded GR in neurogenesis. 
An additional analysis venue that we can follow is to evaluate the basal post-
transcriptional modifications of GR in the RGCs versus IPCs, and specifically the 
phosphorylation status of GR in basal conditions and following DEX-treatment on E14.5. 
Phosphorylation of GR on Ser211 was shown to differ in a cell cycle-phase dependent manner in 
basal unliganded conditions. Furthermore, this Ser211 phosphorylation is maximal during late 
G1 phase and gives the unliganded receptor maximal responsiveness to GCs. Therefore, we 
could explore whether the abundance of Se211 GR phosphorylation differs in RGCs and IPCs 
that are in different cell cycle phases by FACs analysis, both in basal and after DEX exposure 
conditions, following the same setup as for the current study i.e., evaluate GR phosphorylation 
after 24 hours of DEX exposure on E14.5. Furthermore, we can use immunohistochemistry to 
examine whether Ser211 GR phosphorylation is detectable in vivo in RGCs and IPCs.  
Another interesting question, is to see whether a single exposure to DEX on E15.5, which 
is the point that endogenous GC production starts in the mouse embryo, will lead to different 
effects on RGC and IPC proliferation by following a similar approach as we have done for this 
study and also by examining gene expression in RGCs and IPCs. Specifically it would be 
interesting to see whether the normally activated GR versus the now “ultra” activated GR (since 
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in addition to the endogenous GCs, DEX exposure will activate a greater complement of GRs), 
will lead in different effects on the competence of the progenitors. This analysis would allow us 
to determine whether GR has a different role in neural progenitors depending on the 
developmental stage and might explain how prenatal exposure to GCs may result in very 
different effects on brain development and lead to different clinical outcomes in neonates. 
While our study was limited to examination of the effects of premature activation of GR 
signaling by DEX, we can expand our studies by examining in vivo, the effects of the other 
commonly used prenatal GC, betamethasone (BETA). While DEX and BETA, have closely 
related chemical structures, but they have different GR potency and pharmacokinetics (Tegethoff 
et al., 2009) which can lead to different clinical outcomes. Therefore, evaluating the effects of 
Beta on GR signaling properties and subsequently in brain development and neural progenitor 
proliferation and differentiation, would allow us to better understand how selecting a specific 
treatment can affect the developing brain and potentially create better GC alternatives that 
promote only the desired benefits in premature babies while eliminating the possible 
neurological side-effects. 
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APPENDIX A 
DIFFERENTIAL SUBCELLULAR LOCALIZATION OF THE GLUCOCORTICOID     
RECEPTOR IN DISTINCT NEURAL STEM AND PROGENITOR POPULATIONS      
OF THE MOUSE TELENCEPHALON IN VIVO 
 
 
 
 
 147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. GR is expressed in NSPCs and neurons of the E11.5 dorsal telencephalon. (A) z-stack of a sagittal 
section of the dorsal telencephalon stained with BuGR2 (red) and Pax6 (green) and counterstained with 
DAPI (blue). (A, B) Pax6-positive RGCs in the ventricular zone express GR in an apical low, basal high 
gradient. Panel C shows only GR in grayscale. (D) z-stack of a coronal section of the dorsal 
telencephalon, containing part of the lateral ganglionic eminence (LGE) and stained for BuGR2 (red), 
Tbr2 (green) and Tuj1 (blue). PP, preplate; bVZ, basal VZ; Ctx, cortex. 
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Figure 36. GR is expressed in NSPCs and neurons of the E13.5 dorsal telencephalon.  
(A, D) z-stacks of sagittal sections of the dorsal telencephalon on E13.5, immunostained for BuGR2 (red) 
and Pax6 (green) (A) or Tbr2 (green) and Tuj1 (blue) (D). (A-C) RGCs on the apical surface express 
primarily cytoplasmic GR compared to RGCs in the basal ventricular zone (bVZ). The expression profile 
of GR (grayscale) is seen in panel C. (D-F) GR expression in IPCs and neurons (circles outline nascent 
neurons positive both for Tuj1 and Tbr2) is primarily nuclear. CP, cortical plate; Ctx, cortex; LGE, lateral 
ganglionic eminence; SVZ, subventricular zone. 
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APPENDIX B 
PREMATURE ACTIVATION OF GR DURING MIDGESTATION ALTERS NEURAL 
PROGENITOR PROLIFERATION IN A CELL CYCLE DEPENDENT-MANNER    
AND IMPAIRS CORTICAL DEVELOPMENT 
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Figure 37. A single exposure to DEX on E14.5, results in increased body weight on E17.5 but without an effect 
on brain weight. A.  The body weight was increased at E17.5 in two independent litters following DEX 
treatment. Average ± SD; Litter A ncontrol=11, 0.99 ± 0.05; nDEX= 6, 1.37 ± 0.12, p < 0.001; Litter B 
ncontrol=11, 1.16 ± 0.07; nDEX= 12, 1.4 ± 0.09, p < 0.001. B. DEX treatment on E14.5 did not affect brain 
weight proportionally to the effects it had on the body weight. 
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